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i. Abstract English  
 
Pain is an essential part of our survival and keeps us in awareness of our physical limitations 
and protects us from harmful environmental stimuli. However pain and other 
somatosensory sub modalities like vision and smell are rather a perception, a product of our 
brain to handle and bring external sensory inputs to consciousness (10, 18). Regardless of its 
essential role in one’s survival, pain and in particular chronic pain which does not fulfil any 
physiological role, is a major clinical challenge to treat (15, 16). Currently 10 % of the 
population are suffering from chronic pain due to irreversible nerve injury or inflammation. 
Up to now the two major classes of analgesics that are used to treat chronic pain (i.e. non-
steroidal anti-inflammatories and the opioids) focus more on the symptoms of pain than its 
underlying causes.  Recent scientific discoveries obtained from mice in knockout (31,32), 
knock down and overexpression studies as well as analyses of patients suffering from 
unusual pain states (20) show that voltage gated sodium channels are key players in several 
pain pathways. 
In particular Nav1.7, a TTX sensitive voltage gated sodium channel that is mainly expressed 
in sensory DRG neurons and sympathetic ganglia neurons, is fundamental in initiation and 
propagation of action potentials (9- 21, 23) and plays an important role in pain sensation. 
Inherited or spontaneous mutations in SCN9A (Nav1.7) causing a gain of function result in 
hyperexcitability of DRG neurons and lead to Primary erythermalgia (PE) (12,14,21) and 
Paroxysmal extreme pain disorder (PEPD) while nonsense mutations causing loss of function 
of Nav1.7 cause Channelopathy-associated insensitivity to pain (20, 17). 
Interestingly, SCN9A has a corresponding antisense transcript encoded on the opposite 
strand that tail to tail overlaps with the sense transcript and might play a role in regulation 
of SCN9A expression. Different studies have reported independently that natural antisense 
transcripts have an impact on the transcription level of its corresponding sense gene either 
through 1) interfering with its transcription  2) RNAi, RNA editing and RNA masking 3) or 
through epigenetic and chromatin remodelling (1). 
By investigating the possible mechanism of SCN9A antisense transcripts on Nav1.7 
expression, we aim to gain deeper insights into pain pathways and contribute to the 
development of a new specific class of analgesic drugs.    
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ii. Abstract German  
 
Schmerz ist ein wesentlicher Bestandteil unseres Überlebens , er macht uns bewusst wo  
unsere körperlichen Limits liegen und schützt uns vor schädlichen Umwelteinflüssen .  
Schmerzen ,wie auch  anderen somatosensorischen sub Modalitäten wie Sehen, Hoeren 
oder Geruch , eine Wahrnehmung, ein Produkt unseres Gehirns um externe Einfluesse zu 
verarbeiten und zu handhaben  (10) (18). Abgesehen von seiner wesentlichen Rolle das 
eigene Überleben zu sichern , hat nicht jede Art von Schmerz und vor allem chronische 
Schmerzen eine funktionelle Rolle und stellt eine grosse Herausfroderung in der klinischen 
Behandlung da  (15, 16). Derzeit  leiden rund 10% der Bevölkerung unter  chronischen 
Schmerzen aufgrund irreversibler Nervenverletzungen oder Entzündungen.  Die  beiden 
großen Klassen von Analgetika, die verwendet werden, um chronische Schmerzen (dh nicht-
steroidalen Antiphlogistika und Opioide) zu behandeln haben sehr viele Nebenwirkungen 
und ziele nur auf die Bekaempfung  der Symptome ab, anstatt die zugrunde liegenden 
Ursachen zu behandeln. Neue wissenschaftliche Erkenntnisse durch Knockout (31,32) , 
knock down und Überexpression Studien sowie Analysen von Patienten mit ungewöhnlichen 
Schmerzzustaenden (20)  haben zeigt, dass  Natriumkanäle Hauptakteure der 
Schmerzweiterleitung und Prozessierung  darstellen. 
Insbesondere Nav1.7, ein TTX-empfindliche spannungsabheangiger Natrium Kanal, der 
hauptsächlich  in sensorischen DRG-Neuronen und sympathischen Ganglien Neuronen 
exprimiert wird , ist von grundlegender Bedeutung in Initiation und Ausbreitung von 
Aktionspotentialen (9 - 21, 23) und spielt daher eine wesentliche Rolle im Schmerzen 
empfinden . Vererbte oder spontane Mutationen in SCN9A (Nav1.7), die zu gain of function 
Mutationen in Nav1.7 fuehren und in Hypersentitivteat von DRG-Neuronen resultierien, 
fuehren zu Krankheitsbildern wie Primary erythermalgia (PE) (14,12,21) und paroxysmale 
extreme Schmerzstörung (PEPD). Nonsense-Mutationen führen zum Verlust der Funktion 
von Nav1.7 und resultieren in Ionenkanal-assoziierten Unempfindlichkeit gegen Schmerzen 
(20,17). 
Interessanterweise hat SCN9A ein correspondierendes Antisense-Transkript auf dem 
gegenüberliegenden Strang, das  tail to tail angeordent  ist und moeglicherweise  eine Rolle 
in der Regulation der Expression SCN9A spielt. Verschiedene Studien haben unabhängig 
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voneinander gezeigt, dass  Antisense-Transkripte Auswirkungen auf die Expression des 
sense Transkription des entsprechenden Gens haben, entweder durch 1) störung seine 
Transkription 2) RNAi, RNA-Editing-und RNA-Maskierung 3) oder durch Epigenetics und 
Chromatin-Remodeling . (1) 
 
Durch  die Erforschung des Mechnisms durch welchen SCN9A antisense transcript sein 
korrespondierendes sense Gene reguliert , erhoffen wir uns einen tieferen Einblick in die 
molekuaren Zusammenheange die unsere Schmerempfindung beeinflussen und 
steuern.Desweitern erhoffen wir uns dadurch  wesentlich an der Entwicklung einer neuen 
Klasse von Schmerzmitteln beizutragen. 
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1. Introduction   
1.1 Pain perception – Nociception  
 
Pain is like other sensory sub –modalities a perception but in comparison to colour 
perception, pain does not only have a perceptual component but also highly psychological 
and cognitive components (10). In other words, our internal pain scale or how we rate pain 
can change due to severe injury and might influence how we experience pain in the future. 
(60). By contrast, pain research in the last couple of years suggests that our internal pain 
scale is based on our genetic background. In particular, research in the field of nociception 
and voltage gated sodium channels has brought evidence that even single nucleotide 
polymorphisms (SNP) or spontaneous point mutations in these channels can have a 
significant influence on pain thresholds and our internal pain scale (20). 
 
A more generalized definition of what pain is comes from the International Association for 
the Study of Pain (IASP) defining pain as “an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or described in terms of such damage” 
(http://www.iasp-pain.org).  
What is undisputable is that pain is a crucial, non-redundant part of our survival, showing us 
our limits and protecting us from greater harm. This becomes even clearer in patients 
affected by congenital inability to experience pain (20), not feeling any pain at all leads to 
severe injuries and consequently can reduce one’s life expectancy dramatically. Although 
pain is fundamental, chronic inflammatory pain instead does not fulfil any protective 
purpose and strongly decreases a patient’s quality of life. (15) 
 
1.2 DRG neurons: primary afferents and transduction  
 
Nociceptor. Pain sensation is mediated by a special subset of sensory neurons, called 
nociceptors that innervate the tissue with its bare nerve endings. Nociceptors are activated 
through environmental stimuli such as heat, cold, and chemicals.  Activation leads to 
structural changes with corresponding opening and closing of ion channels and subsequent 
alteration of physiological and electrical properties of these channels. The main classes of 
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nociceptors can be distinguished by their afferent fibres, activating stimuli and distribution 
in skin and deep tissue (18). The two main classes of afferent fibres are slowly conducting 
unmyelinated C fibres and fast conducting thinly myelinated Aδ fibres (10). Conduction 
velocity differs between these two fibre types and they are also associated with different 
types of pain sensation.  
First and second pain. In comparison to other somatosensory receptors like 
mechanoreceptors that terminate in specialized structures, nociceptors that mediate pain 
sensation end in bare nerve endings (10). Fast conduction Aδ fibres have a conduction 
velocity of 5- 30 m/s and are involved in first pain sensation, a rapidly perceived pain that 
carries information about what and where an incident happened. By contrast 2nd pain is 
much less informative and discriminative than 1st pain. It is mediated by slowly conducting 
unmylinated C fibres with a conduction velocity of 1m/s (18). 
 
DRG neurons, most of which are nociceptors are pseudo unipolar neurons with their axons 
dividing into classic T junctions with peripheral and central branches. The peripheral branch 
consists of free nerve endings, mainly unmyelinated C fibres that innervate the tissue while 
the central branch projects its axon to 2nd order neurons in the spinal cord (10). Cell bodies 
of nociceptors are found in the dorsal root ganglia and vary in size, sets of channels 
expressed and gene expression. Among a variety of other channels, ion channels like the 
TRP (transient receptor potential) family are found on the axon tip of afferent fibres and 
respond to noxious stimuli such as acid, heat, cold and eicosanoids (15). 
In the presence of a noxious stimulus these ion channels open and create a receptor 
potential that leads to a depolarization of the membrane. Additionally voltage gated sodium 
channels like Nav1.7, Nav1.1, Nav1.6 and Nav1.8 are also found near the peripheral 
terminals of nociceptors and activate when a certain threshold is reached. Mainly the 
activation of Nav1.7 voltage gated sodium channels contributes to initiation and 
propagation of action potentials (28). 
 
2.  Transmission  
2. 1  Voltage gated sodium channels – Introduction  
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Sodium channels are integral membrane proteins containing 4 homologous domains each of 
which consists of 6 transmembrane segments (S1 to S6) (20, 11) that form voltage sensitive 
and ion selective pores (21). These alpha subunits are connected to each other via 
intracellular and extracellular loops (11, 28). The sodium channel’s voltage sensor is found 
in the S4 alpha helix in each of the four alpha subunit domains (I-IV) (11, 20). Voltage sensor 
residues in S4 are either lysine or arginine that are arranged in an interval of every 3rd amino 
acid,  allow only positively charged Na+ ions and only at an appropriate membrane potential 
to enter through the pore by opening or otherwise closing the channel pore (21). 
The molecular weight of the alpha subunits is around 220- 260 kDa and each voltage gated 
sodium channel is associated with auxiliary beta subunits. Four different beta subunits (β1, 
β2, β3, β4) have been identified (19, 21, 25). Beta subunits are single transmembrane 
proteins with an intracellular and extracellular binding domain. Interestingly the 
extracellular domain of β- subunits is homologous to a V-set ( Ig-related domains of non-Ig 
molecules are described as being V -like when they are have a pattern of β-strands: V and V-
related domains have about 65-75 amino acid residues between the conserved disulphide 
bond, and there are four β-strands in each β-sheet plus a short β-strand segment across the 
top of the domain, ( 22 )) of  Ig superfamily  like adhesion molecules.  Still not completely 
understood is what function β subunits fulfil to modulate VGSCs. It is hypothesized that β 
subunits interact with the cytoskeletal and the extracellular matrix (21) via their V set Ig 
domain and thereby might play a role in stabilizing the Nav proteins in the membrane (19) 
or help to even guide Nav polypeptides to membrane sites (19,21,25). Moreover, studies 
using Xenopus laevis oocytes with human β subunits indicate that they even modulate the 
gating properties of the alpha subunit (13). Co-expression of certain α subunits with a 
specific auxiliary β- subunit has been shown to modulate sodium channel properties (13, 19) 
by changing activation / inactivation properties of VGSCs. For example, Nav1.2 co-expressed 
with β1A subunit leads to a 2.5 fold increase in sodium current density due to increased 
channel functionality (21, 25). 
 
All nine pore-forming isoforms (Nav1.1 – Nav1.9) of the alpha subunits are encoded by 
different genes (9- 21, 13, 14) (see Table A). In particular Nav1.1, Nav1.2, Nav1.3 and 
Nav.1.7 are closely structurally and functionally related and are encoded by a set of four 
genes clustered in the chromosomal locus chr.2q24.3. Each of the nine sodium channel 
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isoforms has its own highly specific distribution pattern within the CNS and peripheral 
nervous system (14) (Table A). Nav1.7 is highly expressed in sensory DRG neurons and 
sympathetic ganglion neurons, Nav1.8 and Nav1.9 are primarily found in damage sensing 
DRG neurons and nerve fibres (16, 25). 
In humans, voltage gated sodium channels are highly conserved and show 75 % primary 
sequence homology of the transmembrane and extracellular domains (25). Voltage gated 
sodium channels can be distinguished by their ability to respond to TTX, a tetrodotoxin from 
puffer fish which binds to the ion selective pore (12). Nav1.1 to 1.4 as well as 1.6 and Nav1.7 
are TTX sensitive and respond to nanomolar concentrations of TTX while Nav1.5, Nav1.8 and 
Nav1.9 are even insensitive to micromolar concentrations of TTX (21). 
 
Mechanism of Action 
 
Voltage gated sodium channels mainly contribute to action potential generation and 
propagation. Through their voltage sensor and ion-selective pores they allow the rapid 
influx of Na+ ions during the upstroke of an action potential (9, 13, 14, 15, 16). 
Structural conformation of voltage gated sodium channels changes with changing 
membrane potential and can either be (a) open (active state), induced via membrane 
depolarization; (b) fast inactivated, which occurs when the cytoplasmic loop binds to the 
pore of the VGSC to terminate the sodium flow and leads to (c) closed state: repriming 
(recovery from inactivation), which occurs while the membrane potential is repolarizing to 
get back to the resting membrane potential at -80mV (13). This simplistic view of Nav1 open 
and closed states has been proven to not hold entirely true for all voltage gated sodium 
channels. In particular VGSC found in DRG neurons, where a heterologous set of different 
sodium channels is present, show a more complex pattern of expressing currents. 
Patch clamp experiments with VGSCs identified sodium channels to be either sensitive or 
resistant to TTX. TTX sensitive VGSCs are rapidly inactivating while TTX resistant sodium 
channels slowly inactivate and might serve to prolong the action potential duration due to 
the longer open state of the channels leading to increased neurotransmitter release at the 
nerve terminals (13, 14). 
 
2.2 Nav1.7 a hot spot for human pain disorders 
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SCN9A encodes for the alpha subunit of the TTX sensitive voltage gated sodium channel 
Nav1.7 (9, 16, 20) which is mainly found in slowly conducting (13) small diameter DRG 
neurons and sympathetic ganglion neurons. Nav1.7 is also very weakly expressed in the CNS 
(31). Immunohistochemistry with a specific antibody against Nav1.7 located the sodium 
channel at distal ends of neuritis. Human Nav1.7, (gene symbol SCN9A) is encoded on 
chromosome 2q24.3 and is a 113 kb gene that is comprised of 26 exons which are translated 
into a 1977 amino acid long polypeptide. Nav1.7 is crucial in initiation and propagation of 
action potentials (9-21, 23). Interestingly Nav1.7 is also found in olfactory sensory neurons 
and seems to connect the two sensory modalities, smell and pain. Patients suffering from 
Channelopathy-associated insensitivity to pain and anosmia have loss of function mutations 
in Nav1.7, causing the compromised function of nociceptors and olfactory neurons. (27)  
 
2.2.1 SCN9A protein structure - See Fig2. and supplemental data 1 
 
• SCN9A primary amino acid sequence is 1977 amino acids long.  
• Ion selective pore: a re- entrant loop between helices S5 and S6 is embedded into 
the transmembrane region of the channel to form a narrow, ion selective filter at the 
extracellular end of the pore (35). 
In ion Trans I:  AS 356 - 365 
In ion Trans II:  AS 911 - 920 
In ion Trans III: AS 1390 - 1399 
In ion Trans IV: AS 1682 - 1691 
• Transmembrane regions  
• Coiled coil region  AS 402 - 449 
• Sodium Ion transport associated domain  AS 969 – 1191  
• IQ  AS 1877 – 1899 
• Exon 5 has an alternative splicing variant (57) 
YLTEFVNLGNVSALRTFRVLRALKTISVIP 
YVTEFVDLGNVSALRTFRVLRALKTISVIP 
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• IFM Motif AS 1461 – 1463 , IFM motif and the charged residues in the domain III-IV 
linker identified to be critical for the fast inactivation kinetics of the rat brain II 
channel (36)  
• Tetrodotoxin sensitivity defining amino acid AS Y362 , if this AS is mutated into a 
Serine it turns the channel into a TTX resistant one (37) 
 
2.2.2  Nav1.7 electrophysiological properties  
 
The Nav1.7 voltage gated sodium channel is highly sensitive to TTX and is predominantly 
found in C fibre axons of slowly conducting nociceptive DRG neurons and sympathetic 
ganglion neurons. Nav1.7 rapidly activates and inactivates from the open state within less 
than a millisecond (28) but, unlike other TTX sensitive VGSCs (12)  it slowly recovers from 
fast inactivation (closed state inactivation) (12, 13). By slowly transiting to the closed 
inactivated state, Nav1.7 remains available for activation even with small or through slowly 
depolarizing potentials and serves as a threshold channel for Nav1.8 activation by amplifying 
incoming smaller current. In contrast Nav.1.8 voltage gated sodium channels only open at 
depolarization thresholds higher than Nav1.7 and is responsible for most of the inward 
current in the upstroke of action potentials (14). 
 
2.2.3 Nav1.7 and inflammation  
 
Nav1.7 is associated with inflammatory pain that occurs in response to prior tissue damage. 
Inflammation of the injured tissue leads to hypersensitivity in and around the affected area. 
Inflammatory mediators such as 5HT, prostaglandin and adenosine are released during 
acute tissue damage, (10) enhancing the magnitude of the voltage dependent Nav1.7 
sodium current and shifting the Nav1.7 activating threshold to more hyperpolarized 
potentials. This increases the rates of activation and inactivation dramatically and in a 
second instance leads to increased sensitization of the nociceptors and the inflamed tissue 
(14). Hypersensitivity by increased excitability of a specific set of nociceptive neurons 
promotes healing and repair (12). Furthermore, CFA induced inflammation in mice leads to 
an up-regulation of Nav1.7 expression and increased amount of SCN9A transcripts (30). 
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Nociceptor-specific Nav1.7 k.o (31) and double k.o of Nav1.7 and Nav1.8 (32) confirmed 
Nav1.7’s important role in the development of inflammatory pain.  Interestingly, both the 
Nav1.7 k.o. and the double k.o. are still able to develop neuropathic pain. However, global 
k.o of Nav1.7 in mice is lethal which is likely to be related to the importance of Nav1.7 to the 
sense of smell (29). 
 
2.2.4  Nav1.7 mutations and inherited human pain syndromes 
 
Nociceptive pain primarily functions in detection and protection against potential or acute 
noxious stimuli such as heat, chemical injury, nerve damage and myocardial ischemia that 
causes severe damage, and induces a pain sensation that is highly unpleasant and not 
neglectable. Normally, nociceptive pain persists as long as the external or internal noxious 
stimulus is present. Nav1.7 is linked to three inherited monogenic pain disorders (12). Gain 
of function mutations can result in Primary erythermalgia or Paroxysmal extreme pain 
disorder which are characterised by intensely painful episodes (13) whereas homozygous 
loss of function mutations can result in a congenital inability to experience any pain at all 
(20). 
  
2.2.4.1 Primary erythermalgia (PE) 
 
Inherited autosomal dominant Primary erythermalgia is caused by missense gain of function 
mutations in SCN9A that lead to an increased activity of Nav1.7 due to altered 
electrophysiological properties. Mutations are found in the transmembrane domains and 
intracellular linker domains (9) some of which are in highly conserved parts of the channel 
(e.g. L858H) (14) (Fig 1 overview, PE mutation). All 14 reported PE mutations cause 
lowering of the channel’s activation threshold. This leads to enhanced activity of Nav1.7 by 
shifting the voltage dependence of the channel to more hyperpolarized potentials. 
Moreover the majority of all reported PE mutations also affect the sodium channel’s 
transition to an inactivated state (from open to inactivate). Normally Nav1.7 is a fast 
activating and inactivating channel but certain mutations result it in staying open for longer, 
leading to a larger inward current. Other mutations like I136V, L858F, A863P and F1449V, 
additionally speed up the voltage gated channel’s repriming (recovery from inactivation). 
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Also a correlation between certain mutations and age of PE onset has been determined. 
Mutations such as I848T are linked to early onset of PE while others like Q10R are linked to 
late onset which only leads to a small shift in activation threshold toward more 
hyperpolarized membrane potentials.  
Clinical symptoms characteristic for PE:  First clinical symptoms in patients suffering from 
PE appear in the first decade of their life with reddened feet and hands due to moderate 
physical exercising, exposure to warmth and/or after long periods of standing (14). In the 
later course of PE, there are episodes of persistent burning pain and redness of lower 
extremities which can extend to the upper legs, feet, and often hands which is accompanied 
by elevated temperature of the affected areas (9, 14). 
 
2.2.4.2 Paroxysmal extreme pain disorder (PEPD) 
 
PEPD is an inherited autosomal dominant disease characterized by sudden onset and 
reoccurring episodes of burning pain in different body parts. PEPD is caused, similar to PE, 
by mutations in SCN9A that lead to a gain of function in Nav1.7 (see fig1 overview PEPD 
mutations). In comparison to PE, all mutations that are found in Nav1.7 evoking PEPD (14, 
28), do not enhance the voltage gated sodium channels activation but instead they impair 
its voltage dependent steady state inactivation. Most, but not all of the reported mutations 
that cause paroxysmal extreme pain disorder, shift the steady state inactivation to a more 
depolarized potential. This leads to incomplete inactivation of Nav1.7 (15), and decreases 
the actual threshold for initiation of the action potential and increases the number and 
duration of evoked AP in DRG neurons leading to hyperexcitability of these neurons (34). 
 
Clinical symptoms of PEPD: Patients with PEPD suffer from excruciating painful episodes 
that primarily affect the rectal, submandibular and ocular regions. (14). Patients with PEPD 
are strongly affected during their childhood with reoccurring and stronger painful episodes, 
(34) often accompanied with non-epileptic seizures and cardiac symptoms (14, 29, 34). 
Interestingly in most individuals, PEPD symptoms diminish with age although there are a 
number of cases where PEPD was carried into their adulthood (28). 
 
4 characteristic stages are defined in PEPD (12, 14) 
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1. Stage, directly after birth, new-born has red flushes all over the back, legs, and soles 
of the feet. 
2. Stage, rectal pain, childhood: burning pain that suddenly appears and lasts for at 
least 1h. The burning pain slowly moves down to the lower extremities followed by 
red flushes on the soles of the feet, skin, scrotum, left and right foot and  buttocks 
3. Stage, Ocular pain pattern, childhood: sudden onset of acute burning pain that lasts 
for a couple of minutes, followed by sporadic redness of skin, in particular in the 
temporal region and eyelids.  
4. Stage, paroxysmal pain 
 
Painful episodes are induced by eating hot, cold or spicy food; and by sunlight and strong 
wind. It is remarkable that although Nav1.7 is widely expressed within the PNS, PE and PEPD 
both show a highly specific tissue distribution of symptoms (14). This strong variation 
among these two diseases gives rise to the idea that Nav1.7 is probably not the only, but 
definitely an important part in developing PE and PEPD. 
 
2.2.4.3 Channelopathy-associated insensitivity to pain (CIP) 
 
CIP is a very rare inherited autosomal recessive disorder caused by recessive loss of function 
mutations in SCN9A. First insights into this highly unusual pain state were obtained through 
analysis of three consanguineous families from Pakistan (20). 
Due to the frameshift or the nonsense amino acid changes in either exon 10 (S459X), 13 
(I767X) and exon 15(W897X) (14), SCN9A mRNA does not encode for a functional protein in 
these families. (For all reported mutation in SCN9A see Overview fig1 CIP). Most patients 
suffering from CIP are from consanguineous families and are homozygous for the same 
mutation in SCN9A (9) and are from birth insensitive to painful stimuli but still respond to 
light sensation of touch, warm, cold, proprioception and pressure (20). While nociception is 
completely lacking in these individuals, any other physical and mental deficiencies could not 
be found. Despite having quite severe injuries that mainly go unnoticed and suffering from 
anosmia (27), they have an otherwise normal development, intelligence and health (20, 29). 
What is still not completely understood is why global Nav1.7 k. o in mice is lethal but in 
humans loss of functions mutations causes  channelopathy associated insensitivity to pain in 
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otherwise healthy individuals. One explanation is that new-born mice with loss of Nav1.7 
function are not able to find their mother’s mammary gland and die due to malnutrition. 
Interestingly mouse Nav1.7 shows a higher expression in the CNS compared to human 
Nav1.7, in particular in the brain nuclei such as the paraventricular hypothalamic nucleus 
and the supraoptic nucleus (9). Furthermore, variability in inter-human pain sensation can 
be caused by polymorphisms in SCN9A (14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig1 Overview of reported mutations in SCN9A causing PE (IEM), PEPD and CIP (9) 
Mutations reported in patients suffering from PE are found in the intracellular loops as well 
as in the conserved parts of the transmembrane domains of Nav1.7. PEPD mutations are 
mainly found in the intracellular linker regions. PE, PEPD are inherited autosomal dominant 
disorders whereas CIP is caused by inherited autosomal recessive mutations in SCN9A. PE 
enhances the channel activation, PEPD impairs Nav1.7 channel inactivation both leading to 
increased channel activity which is linked to hyperexcitability of DRG neurons. 
 
2.2.5 Other voltage gated sodium channels and associated pain syndromes  
 
2.2.5.1 Nav1.3 and neuropathic pain  
Fig1 Overview of all reported mutations in SCN9A causing PE (IEM), PEPD and CIP 
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Nav1.3 is a TTX sensitive voltage gated sodium channel mainly expressed in the adult central 
nervous system and during embryonic development. Its expression levels are normally very 
low in the PNS. Expression of Nav1.3 and β3 subunit in sensory but not primary motor 
neurons is only up-regulated due to nerve injury.  Nerve injury also alters the level of 
neurotrophic factors like NGF and GDNF and reactivates the transcription of the normally 
transcriptionally silenced Nav1.3 VGSC (30, 25).  
It was postulated that Nav1.3 up regulation might render DRG neurons hyperexcitable 
during nerve injury. This hypothesis was explained by Nav1.3 channel biophysical properties, 
fast inactivation after activation and fast repriming, while slowly inactivating from the 
closed state. The slow transition into a closed state, similar to Nav1.7, enables Nav1.3 to 
remain available for activation by small depolarizing potentials (30, 25). However Nav1.3 
global and DRG specific k.o. mice do not show any amelioration in pain behaviour after 
nerve injury and is therefore not responsible for the hyperexcitability of DRG neurons seen 
after nerve injury. 
 
2.2.5.2   Nav1.8 inflammation and neuropathic pain  
 
Nav1.8 is a TTX resistant voltage gated sodium channel which is mainly found in free nerve 
endings of DRG neurons and in trigeminal ganglia (25). Its location at free nerve endings 
enables Nav1.8 to strongly contribute to the level of neuronal excitability and modulate and 
influence pain signalling significantly (21).  
Electrophysiological properties: Nav1.8 is a slowly inactivating (transition from open to 
closed state) and fast repriming TTXr channel thus activation and inactivation occurs at 
depolarized and voltage dependant potentials (25). Nav1.8 is the most significant VGSC in 
the depolarization phase of action potentials in DRG neurons.  
Interestingly, inflammatory mediators like NGF influence the expression level of Nav1.8 and 
TTXR current levels while others like prostaglandin E2 and serotonin shift the channel 
activation to more negative potentials by phosphorylation of specific serine residues via 
intracellular 2nd messenger proteins PKA/C (21, 25, 30). This means that inflammation 
results in an increased activation and inactivation of the VGSC. Nav1.8 k.o mice confirmed 
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its contributory role in inflammatory pain and surprisingly also in cold evoked pain but no 
clear evidence for a role of Nav1.8 in neuropathic pain has been determined (43). 
 
2.2.5.4  Nav1.9 
 
Nav1.9 is similar to Nav1.8 as this channel is predominantly expressed in small diameter 
nociceptive DRG neurons (25, 30). In comparison to Nav1.8, Nav1.9 expresses a permanent 
TTX resistant current due to its activation and inactivation properties at hyperpolarized 
potentials, which are around the cell’s resting membrane potential (13). The TTX resistant 
current expressed by Nav1.9 is mostly similar to the Nav1.5 cardiac current (25). Nav1.9 
mainly contributes to the setting of DRG excitability by modulating the resting potential but 
due to its slow activating channel properties it does not engage in the depolarization phase 
of action potentials, like Nav1.8 does. Nav1.9 k.o and knock down mice treated with CFA 
expressed a reduced sensitivity to heat and mechanical pain suggesting a role for Nav1.9 in 
neuronal inflammatory pain, although there were no reported changes in Nav1.9 current 
properties (54). By contrast Nav1.9 k.o. does not influence acute pain and neuropathic pain 
thresholds. 
 
2.3 Future prospective – a new desirable class of drugs  
 
Currently two major classes of analgesics are used to treat chronic inflammatory pain:  
a) Non-steroidal anti-inflammatory drugs (taking hold through acting on arachidonic acid 
metabolism) and b) Opioids (acting on G proteins). However, these drugs can often be 
accompanied by severe side effects such as gastrointestinal bleeding (NSAIDs) and 
respiratory depression (opioids). Furthermore, the opioid class of drugs have issues 
associated with addiction and tolerance (15). To understand how pain works and to 
design new classes of drug that specifically target the source of pain rather than just only 
treating its symptoms, it is crucial to understand how noxious stimuli are transduced, 
transmitted and processed within the PNS and CNS. Nav1.7 plays a key role in nociception 
and inherited pain disorders and mutations within this gene can have drastic impacts on 
pain sensation. Although Nav1.7 gain of function (PE and PEPD) and loss of function (CIP) 
mutations 
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cause a spectrum of human pain disorders and anosmia (27), this voltage gated sodium 
channel does not seem to be involved in any other major pathway apart from pain and the 
sense of smell, which makes it an attractive target for a new class of analgesic drugs. 
 
 
 
 
 
 
 
VGSC Chrom. Tissue TTXs Symptoms/Disease   Reference 
Nav1.1 2q24.3 CNS/PNS + Epilepsy, Migraine Dichgans et al 2005(61) 
Nav1.2 2q24.3 
 
CNS +  Ko:Brainstem Apoptosis 
followed by severe Hypoxia,  
Planell-Cases, 2000(24) 
Nav1.3 2q24.3 
 
Adult :CNS 
Low level in DRG 
Embryonic DRG  
+ Up regulated in mice with  
normal acute  and 
inflammatory pain 
Nassar et al2006(33) 
Nav1.4 17q23.3 
 
Skeletal muscle  + Hyperkalemic periodic 
paralysis 
Lerhman-Horn et al., 
2002(26) 
Nav1.5 3p22.2 Heart/CNS - Visceral pain  Wilde et al 2011 (65) 
Nav1.6 12q13.13 CNS + Impaired motor function  Levin et al2006 (66) 
Nav1.7 2q24.3 
 
DRG and 
sympathetic neurons 
+ PEPD, PE , CIP ,chronic 
inflammatory pain 
Congenital pain disorder 
Nassar et al 2004(31) 
,Fertelman et al 2006 
(62) 
Cox et al 2008(20) 
Nav1.8 3p22.2 
 
DRG _ Cold pain , inflammation 
SNP in heart expressed 
Nav1.8 increases the risk of 
aterial fibrillation and heart 
attacks  
Nassar et al 2005, 
Akopian et al (64) 
 
Nav1.9 3p22.2 
 
 
DRG _ Inflammation  Priest et al 2005(63) 
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3. Natural antisense transcript (NAT) 
 
The Human Genome Project offered a profound insight into how genomes are arranged and 
how little of its actual size consists of coding regions, suggesting that the complexity of life 
may not only lie within coding sequences. Technical improvements over the last decade led 
to the rather unexpected finding of extensive bidirectional transcription of eukaryotic genes. 
Some of these antisense transcripts result in pairs of sense and natural antisense transcripts 
that overlap and which maybe hybridise and even regulate each other’s expression (7). 
Natural antisense transcripts or NATs are widely distributed throughout the human and 
mouse genome, but were first misinterpreted as transcriptional noise. The high number of 
NATs encoded in the genome suggests rather an evolutionary benefit from such a genomic 
arrangement. More evidence through high-throughput methods suggests a potential role of 
natural occurring antisense transcripts as transcriptional units like other regulatory RNAs 
(2).  
 
3.1 Classification of NATs 
 
Classification of NATs is related to their genomic location and their orientation to their 
corresponding sense transcript. 
Classification according to their genomic location means that NATs are either in cis or trans. 
Cis-NATs are encoded on the same genetic loci and are perfectly complementary to the sense 
transcript. Trans-NATs are transcribed from different loci and are often shorter in size (5) and 
display an imprecise pairing with the sense transcript (3). A related class of transacting non 
coding RNAs are microRNAs and snoRNAs (4). Another approach to classify NATs applies to 
the orientation of the antisense transcript in comparison to the sense transcript. Possible 
genomic arrangements are (A) head-to-head 5’-5’ or divergent NAT (B) tail-to-tail 3’-3’or 
convergent NAT (C) fully overlapping and (D) non overlapping NAT (see Fig 3). Regarding their 
encoded information, NATs can be protein coding containing an open reading frame or non–
coding, with both variants having different regulatory potentials (3). 
The length of natural antisense transcripts varies strongly between a 100 bp up to several 
thousand base pairs with a minimum sense overlap of 20 bp (3, 7). NATs are tissue and cell 
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specifically expressed but their expression level is often relatively low in comparison with 
their corresponding sense transcript which makes them quite difficult to detect and amplify 
(5, 6). 
 
3.2 NAT detection strategies and pitfalls 
 
Defining what is the sense and which one is the antisense gene occurs based on several key 
points that define the sense and antisense genes.  A) if both transcripts are encoding a 
protein or if one is non-coding then the non-coding refers to the antisense gene B) 
expression pattern, the higher expressed gene is the sense copy C) mostly but not only  the 
sense mRNA undergoes splicing and has longer intronic sequences.  
Commonly used detection strategies to identify NATs are cDNA clones, EST libraries 
combined with exon – intron splicing sites and detection of poly a – tails. While the dominant 
fraction of NATs are nuclear restricted, non-coding and mostly not poly adenylated or spliced 
there are exceptions which are then excluded from detection methods using these criteria. 
Consequently the number of NATs is probably even higher than previously expected (5). 
Natural occurring antisense transcripts can also undergo splicing or arrive from intronless 
genes. Other pitfalls in detection of NATs and interpretation of high throughput screening 
and expression data arises also from varying NATs length for instance trans- NATs are 
commonly shorter (5). There is strong evidence that sense genes with an overlapping 
antisense transcript have a coordinated expression pattern which can be either positively or 
negatively regulated Fig.2. (5, 6, 7) 
 
3.3 Antisense transcription  
  
Approximately 15 to 20 % (1, 2, 5, 6 7) of all the coding mammalian genes and slightly less in 
plants (7) have an overlapping coding or non-coding natural antisense transcript (5). 
As NATs occur in such a high density throughout the genome then this implies an evolutionary 
benefit of such a genomic arrangement (7). However, the evolutionary conservation of the NATs 
may not be primarily on the sequence level, as non-protein coding NATs genes have a quite a low 
conservation (5). NATs are unequally distributed on the autosomes and X chromosomes, with 
underrepresentation of exonic overlapping NATs on the X chromosome which gives evidence to 
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evolutionary pressure on NATs. Regarding the common structural characteristics of NATs it 
points out that there is a conserved mechanism of regulation (6). 
 
3.4 Functional and biological role of natural antisense transcripts  
 
A clear advantage for RNA mediated transcriptional regulation is given by its quick 
production and degradation, its local storage, conformational flexibility, distribution, and its 
ability to interact with both nucleic acid and protein (5). Furthermore by using RNA 
transcripts as intermediate transport and information forms, cells can precisely direct spatial 
and local expression of proteins. Natural occurring antisense transcripts provide a new level 
of RNA based transcriptional regulation that is distinct from the already known epigenetic 
mechanisms of regulating transcription such as DNA methylation and histone acetylation 
(See Fig2). 
 
3.4.1 RNA–antisense RNA interaction: RNA editing, RNAi and RNA masking 
 
3.4.1.1  RNA editing   
 
After being transcribed from the DNA strand, pre mature RNA undergoes a variety of 
maturation steps, such as 5’ capping, splicing and 3’ processing and polyadenylation (40). 
Another post transcriptional mechanism is RNA editing. Several different types of RNA 
editing (39) are known which alter the target mRNA sequence by a) addition or deletion of 
nucleotides or b) changing one nucleotide to another (40). The most popular form of this 
post transcriptional site specific alteration is the conversion from A-> I (Adenosine to 
Inosine) in dsRNA through an enzyme called ADAR (adenosine deaminase acting on RNA). 
Inosine base-pairs with cytosine and is functionally equivalent to guanidine (38).  
Adenosine deaminase acting on RNA (ADAR). RNA editing occurs only in dsRNA although 
the length of the ds region that is targeted by editing can vary. Three different ADAR 
enzymes (ADAR1, ADAR 2 and ADAR3) are found in humans and are widely present 
throughout different tissues, except for ADAR3 which is only found in the CNS. Within a cell 
ADAR1 and ADAR2 have a specific subcellular distribution, ADAR1 and its 2 isoforms ADAR1L 
(long splicing transcript) found in the cytoplasm and ADARS (short splicing transcript) 
  
23 | P a g e  
 
present in nucleolus and nucleoplasm whereas ADAR2 is found only in the nucleolus. This 
distinct cellular distribution gives an idea of where the substrates they recognize are located 
(40). ADAR mutation or alterations in the RNA editing machinery are also linked to a various 
human diseases, such as depression, ALS, neuronal apoptosis and Dyschromotosis 
symmetrica hereditaria (38, 42). 
 
RNA editing and natural antisense transcripts. The biological role of RNA editing lies in fine 
tuning  protein function, RNAi , modulating neuronal signals and control of microRNA 
function (38,40). Through RNA editing genetic diversity is created, one gene can give rise to 
a set of slightly different proteins while not abandoning the original one. But for one gene or 
mRNA to be edited by ADAR it must be present in a double stranded structure, either 
through forming a loop within its own structure or by nuclear duplex formation with its 
corresponding antisense transcript (44). Most of the reported A-to I editing sites are found 
in Alu repeats and long interspersed elements (LINES), which are mainly located in 
untranslated UTR regions of the mRNA (40). It was hypothesized that sense and antisense 
transcripts may form a nuclear RNA duplex that can serve as substrate for the RNA editing 
machinery, leading to the degradation, nuclear retardation or creation /destruction of 
splicing sites within the sense transcript (1).  Rnp4f gene and its correspondent NAT Sas10, 
is a prominent RNA editing case reported from Drosophila melanogaster where a sense 
antisense pair undergoes RNA editing (44). However there is no evidence yet supporting a 
role of RNA editing in human and mouse sense-antisense pairs (1). 
 
3.4.1.2  RNAi 
 
RNAi is a highly conserved response and defence mechanism against dsRNA that triggers 
sequence specific post transcriptional silencing. RNAi therefore acts as an antiviral defence, 
influences gene regulation and genomic stability, protects against transposons and inhibits 
genomic rearrangements during differentiation. 
 
SiRNA and miRNA. Although they share one common feature i.e. their length (~20 -24nt), 
siRNA and miRNA differ strongly in their origin and regulatory function. SiRNA derives from 
viral DNA and transposons and are transcribed by RNA polymerase II, and exported into the 
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cytoplasm. MiRNA derives from genomic sequences and are transcribed by RNA polymerase 
III. Pri-miRNA is processed by Drosha and also exported into the cytoplasm. 
In the cytoplasm an RNA III nuclease, DICER, binds to the dsRNA molecules, unwinds and 
cleaves them into small RNAs. The passenger strand is degraded, while the small RNA 
accumulates and is recruited by RNA induced silencing complex, RISC (53). RISC incorporates 
the ssRNA molecule and induces siRNA gene specific silencing. MiRNA can also induce gene 
specific silencing, while also target other genes at the same time, or regulate gene 
expression. SiRNA are homologous to their target RNA while for miRNA the degree of target 
complementarity determines its function, either as a silencer or a transcriptional regulator 
(40). 
RNAi and NATs. It has been suggested that sense and antisense RNA duplexes may be 
processed by Dicer and mediate RNA induced silencing. Evidence for this RNAi mediated 
NAT mechanism is by now only proven to occur in Arabidopsis where salt tolerance is 
regulated by siRNA formation which is encoded by a pair of tail to tail overlapping sense and 
antisense pairs. But here both sense and antisense transcripts are coding for two stress 
related genes P5CDH (sense) and SRO5 (antisense). P5CDH is expressed under normal 
physiological conditions. Due to altered salt concentration the transcription of SRO is 
induced leading to duplex formation of sense and antisense transcripts and down regulation 
of P5CDH through cleavage of its mRNA. There have not yet been any reported cases of 
RNAi- NAT mediated regulatory mechanisms in mammals. (1). 
 
3.4.1.3 RNA masking 
 
Unlike RNA editing that occurs in the nucleus, RNA masking takes place in the cytoplasm 
(44). Sense and antisense RNA or more general ssRNA folds up into hairpin structures and 
masks binding sites for transcription factors or miRNA, splicing sites or influences the 
stability and translation of the sense mRNA (1). 
 
Prominent examples for RNA masking. BACE1 (β site - amyloid precursor protein cleaving 
enzyme) which is involved in Alzheimer’s disease, shows an increased stability when its 
corresponding antisense transcript is present (8). Through duplex formation with BACE1 
antisense transcript, a miRNA binding site is masked (45). Another well studied example of 
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RNA masking is the HIF (hypoxia inducible factor) that is activated due to low oxygen 
conditions. Two main splice variants of HIF-1α and HIF-2α are known, they show distinct 
functionality during embryogenesis (46). The expression of HIF1-α antisense transcript alters 
the mRNA stability of one splicing variant dramatically by altering its 2nd structure and 
exposing an Alu rich element and leading to its decay (44, 45). Recent findings discovered 
that p53, the main tumour suppressor and guardian of the genome whose loss of function is 
a major cause of cancer, has a corresponding antisense Wrap53. Wrap53 stabilizes p53 
mRNA leading to an increase in both mRNA and protein levels of endogenous p53. Protein 
levels are enhanced by Wrap53 targeting the 5’ untranslated region and marking it for siRNA 
(45,48)
 RNA masking which results in correlated expression levels of sense and antisense 
transcript (1) See figure 2 (B).  
 
3.4.2 DNA–RNA interactions: transcriptional interference, epigenetics 
 
3.4.2.1 Transcriptional interference  
 
Transcriptional interference is based on the assumption that transcription occurs only in one 
direction at a given time (44). As sense and antisense transcripts are encoded on opposite 
strands, RNA Polymerase II simultaneously transcribes from each strand but the 
transcriptional apparatus might collide in the overlapping regions (1). Transcriptional 
interference leads to either a non-correlated, inverse expression pattern or a complete stop 
of transcription on both strands. A study on the effect of length and type of the overlap of 
sense-antisense genes on their expression level found a correlation. The length of the 
overlapping regions that were up to 200bp showed the highest  sense and antisense co-
expression whereas co-expression decreased to zero at overlapping lengths >2000bp. This 
proves the longer the overlap the more likely is transcriptional collision. Head to head, tail 
to tail and fully overlapping are the three types of orientation of sense and cis NATs. The 
way they are oriented to each other has also an impact on their expression level like length 
does. Head to head orientation and fully overlapping NATs show a decreased co-expression 
pattern than tail to tail sense–antisense orientated NATs (47). 
 
Prominent examples of transcriptional interference: Gal7 and Gal10. 
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Due to transcriptional collision of RNA Polymerases II in the overlapping area, sense and 
antisense transcripts exhibit an inverse expression pattern see fig2 (A) (1). What is still 
controversial is the role of transcriptional interference as the main regulatory mechanism 
for NATs. First this approach requires that sense and antisense RNA are transcribed 
simultaneously from only one allele. This is often not the case either and the time point of 
transcription can vary between sense and antisense transcripts or the transcript from 
different alleles, maternal or paternal. This might explain why the X chromosome shows 
relatively low levels of antisense transcription (i.e. gene dosage, one X chromosome is 
inactivated) (44). 
 
3.4.2.2 Chromatin remodelling and epigenetics  
 
Chromatin remodelling is induced by altered methylation, acetylation or phosphorylation 
states leading to chromatin decondensation or condensation, which makes certain genes 
accessible or inaccessible for transcription. It has been suggested that NATs play a role in 
DNA methylation by directly interacting with methylases or influencing chromatin 
modifications of non-imprinted autosomal genes by recruiting histone modifying enzymes 
(44). The proposed mechanisms by which NATs alter expression and influence chromatin 
condensation, is through suppressing transcription of the sense gene by binding to its 
promoter region and in a 2nd instance recruiting histone remodelling enzymes, like 
deacetylases and methylases (1, 44). Several well characterized cases of NAT mediated 
transcriptional silencing are reported, where binding of antisense to regulatory DNA 
sequences induces trimethylation and heterochromatin formation see fig 2 (D). 
 
For example, CDKN1A (p21) encodes for a cyclin dependant kinase inhibitor which is a well-
known tumour suppressor gene that is regulated by its corresponding antisense transcript. 
CDKN1A antisense expression recruits and mediates trimethylation at the sense promoter 
region. Highly interesting in this case, is that a synthetic 21bp long dsRNA targeting the p21 
promoter region causes a phenomenon described as RNAa (RNA activation) leading to p21 
expression (52). 
Through Dicer k. o. studies, where heterochromatin formation was drastically impaired, it 
was proposed that RNAi and chromatin remodelling might work in concert (51). More 
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evidence supporting a role for NATs in epigenetics is based on the finding that chromatin 
binding enzymes have conserved RNA binding motifs, giving rise to the idea that NATs are 
local modulators of chromatin remodelling enzymes. Another very interesting aspect is that 
NATs have a relatively low expression level but their impact on sense expression can be 
dramatic, suggesting epigenetics as a central mechanism of NAT mediated transcriptional 
regulation due to its low copy number requirements. There are only two alleles of each 
gene in a given healthy cell, if NATs directly interact with DNA, then theoretically only 2 NAT 
copies per cell would be required to suppress or modulate gene expression (44). Moreover, 
antisense expression reaches its peak before and during recombination and is believed to 
induce opening up of chromatin structures during recombination (1).  
 
Genomic imprinting describes the phenomenon of an inherited monoallelic expression, 
where either the maternal or paternal allele of a gene is expressed. Around one hundred 
and sixty imprinted genes are reported most of which are found in small clusters (53). For 
several cases of genomic imprinted genes, chromatin remodelling and DNA modifications 
are induced by natural antisense transcripts (6, 7, 8, 44). 
 
Prominent example: X chromosome inactivation. X chromosome inactivation is required to 
regulate gene dosage in female mammals. First during an early stage of embryonic 
development, only the paternal X chromosomes are inactivated which is reversed in the 
early blastocyst. One of the two inherited paternal or maternal X chromosomes will be 
randomly inactivated during embryogenesis. X inactivation, the transition from eu- to 
heterochromatin that is firmly packed, is controlled by the Xic (X inactivation centre) where 
four non protein coding genes are found. The Xic is crucial for X inactivation and encodes 
Xist, Tsix, Jpx and Ftx. Xist, a long non coding RNA is weakly expressed from both X 
chromosomes but is relatively unstable (50, 44). Due to changes of either stability or to sex 
specific induction of transcription the expression level of Xist increases from the prospective 
inactive chromosome, Xist spreads, binds and coats the future inactive chromosome (55). 
Further Xist coating recruits histone methylases and leads to chromatin condensation (1). 
On the same locus, on the opposite strand, downstream of Xist a natural antisense 
transcript Tsix is encoded. Tsix is a non-coding 40 kbp long, nucleus restricted RNA that is 
also weakly expressed from both chromosomes before onset of X inactivation (50). While 
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the inactive X chromosome enhances Xist expression, the remaining active X chromosome 
increases the expression of its antisense gene Tsix (1). 
 
Although it is still not fully understood through which exact mechanism natural antisense 
transcripts influence chromatin remodelling, in most cases the expression of a whole cluster 
of genes is altered. For chromatin remodelling, an inverse expression pattern between 
antisense transcript and all genes in the cluster is predicted (1) see fig 2 (D) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2 Left: OVERVIEW: Possible regulatory mechanisms by which NATs can influence expression 
levels of corresponding sense transcripts. Mechanism of antisense action (A) Transcriptional 
interference (B) Alternative Splicing (C) RNA editing and RNAi (D) Chromatin remodelling Right: 
Relationship between sense and antisense mRNA levels (1) 
 
4. SCN9A and its corresponding antisense transcript  
 
The human and mouse SCN9A/Scn9a sense genes both have a corresponding antisense 
transcript organised into a tail to tail arrangement (i.e. 3’ ends overlapping). The sense-
antisense overlapping region in human is approximately 500 bp while in mouse it is around 
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180bp. Both antisense transcripts in mouse and in human are non-protein-coding and have 
a total length of 2352bp and 1347bp respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3 Natural antisense transcripts and sense transcript can have four different genomic 
arrangements: head-to-head 5’-5’, divergent NAT (B) tail-to-tail 3’-3’, convergent NAT (C) fully 
overlapping   (D) no- overlapping.  A:  Tail-to-tail arrangement of human Nav1.7 antisense gene 
(BC051759) and SCN9A on chromosome 2 (genome uscs) (B) tail to tail arrangement of the mouse 
SCN9a antisense gene on chr.2. Size of the sense-antisense overlapping region for mouse ~180bp 
while for human ~500bp. 
 
 
 
 
 
 
 
 
A 
B 
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5.  Material and Methods 
 
5.1        Gels, LB and Plates  
5.1.1 Agarosis gel 0.9 %, 1.62 g agarosis in 180ml 1x TAE Buffer  
5.1.2 1kb Ladder Invitrogen see appendix AP 1.1 
5.1.3 100bp Ladder Invitrogen see appendix AP 1.2 
5.1.4  LB 10 g LB broth in 500ml ddH20. Mixed by hand and autoclaved for 20 min at 121 
degrees  
5.1.5 LB Agar  10 g LB and 7.5 g Agar broth in 500 ml ddH20 autoclaved for 20 min at  121 
degrees and cooled down to ~42 C 
5.1.6 Antibiotics added to LB or LB+Agar  Ampicillin (100ug/ml) or Kanamycin (25ug/ml)  
 
5.2.  RNA isolation 
 
Deeply anesthetize mice with CO2 and terminate through neck breaking, dissect DRGs, and 
bring freshly dissected DRGs into RNAlater (Qiagen 11560622) or dissection medium. 
Remove nerve strings and store for maximum one week in RNAlater at 4C. 
• Dissection medium: HBSS w/o Ca2+and Mg2+, HEPES (Gibco 15630-049) 5mM, 
Glucose 10mM (Sigma) 
Clean glass homogenizer by washing with tap water and 1 time with RNaseZap (Ambion 
9782) and three times with 1 ml of DEPC-treated water. Finally wash glass homogenizer with 
0.5 ml of TRIzol. Add 0.6 ml TRIzol (Invitrogen 15596-026) into homogenizer and transfer 
dissected DRGs into the glass homogenizer. Mixture is left incubating 3-5 minutes at room 
temperature. DRGs and TRIzol are carefully homogenised by hand for at least 1-2 min but 
maximum 3 minutes. Sample volume of approximately 700ul is brought onto a QIAshredder 
mini column (Qiagen 79654). Spin full speed at 13k rpm for 2 min, column is removed and 
supernatant is centrifuged for another 3 minutes at full speed. Transfer supernatant into 
PLG tube (Phase-lock Gel, heavy (VWR 713-2536)). Spin at ~16,000xg for 20 seconds before 
use. Measure the volume of supernatant with a pipette. 2/10th of sample volume of 
chloroform is added to the sample (or chloroform isopropanol alcohol 24:1). Mixture is 
shaken vigorously by hand for 15 seconds and left to stand for 3 min. Spin (~16,000xg) for 
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15 min at 4ºC. Carefully remove the upper colourless aqueous layer using a p10 tip to 
recover the final drop, and place into a fresh 1.5ml tube. Measure the volume of this 
aqueous phase with a pipette.  Slowly add an equal volume of 70% ethanol to the aqueous 
phase. Gently mix by pipette and transfer the sample to an RNeasy MinElute spin column 
(Qiagen 74204) place in a 2 ml collection tube. Close the lid and spin for 15 seconds at 
16,000xg. Discard the flow-through. Place the RNeasy MinElute spin column in a new 2 ml 
collection tube. Add 500 µl Buffer RPE to the spin column. Close the lid and spin for 15 
seconds at 16,000xg. Discard the flow-through. Pipette 80 µL of the DNase I/Buffer RDD mix 
onto the membrane, leave at RT for 15min. Close the lid and spin for 15 seconds at 
16,000xg. Discard the flow-through. Add 500 µl Buffer RPE to the spin column again. Close 
the lid and spin for 15 seconds at 16,000xg. Discard the flow-through. Add 500 µl 80% 
ethanol to the spin column. Close the lid and spin for 15 seconds at 16,000xg. Discard the 
flow-through. Put the RNeasy MinElute spin column in a new 2 ml collection tube. Open the 
lid of the spin column, and spin at full speed for 5 min, put the RNeasy MinElute spin column 
(Qiagen 74204) in a new 1.5 ml collection tube. Add RNase-free water (Invitrogen) directly 
to the centre of the spin column membrane. Close the lid gently, and spin for 2 min at full 
speed to elute the RNA. Measure the RNA concentration with Nanodrop and store at –80 
degrees.  
 
5.3        Cloning, Kits and PCR  
 
5.3.1    OneShot© Top10 chemically competent cells (Invitrogen C4040-10) 
             For protocol see Appendix AP1.3 
5.3.2 XL10-Gold ultracompetent Cells (Stratagene C- 200314).  
For protocol see Appendix AP1.4 
5.3.3 Miniprep (Qiagen Spin Miniprep kit). For protocol see appendix  AP1.5 
5.3.4 Maxiprep protocol see appendix Qiagen High speed Maxiprep kit. For protocol see 
Appendix AP1.6 
5.3.5 Gel purification see appendix AP1.7 Qiagen Gel purification kit  
5.3.6 PCR Purification  Qiagen see Appendix AP1.8 
5.3.7 DreamTaq Green DNA polymerase kit AP 1.16 
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5.4 Restriction digests 
• Single Digest: 15 μL of H2O, 2 μL of appropriate restriction enzyme buffer, 2 μL of 
DNA (200ng), 1 μL of restriction enzyme. Leave 3hours at 37°C or 65 °C 
• Double Digest: for 2 restriction enzymes, use 1 μL of each enzyme with 2 μL of 
buffer, 2 μL of DNA (200 ng) and 14 μL of H2O. 
Enzymes used EcoRI, BamHIII, BstBI, BsaAI, KpnI, HindIII (New England Biolabs) 
 
5.5 SuperScript RT ( Invitrogen) see Appendix AP 1.9 
5.6 Phusion high fidelity PCR kit, Finnzymes F-553S/L protocol see Appendix AP1 .10 
5.7 Ear DNA Extraction for PCR – Isolation of Genomic DNA  
 
Collect ear tissue in 0.5 ml tube using an ear puncher. If not extracting DNA immediately, 
store tissues in freezer. Prepare enough lysis mixture for all samples plus a bit extra (i.e. if 
you have 10 samples, make up enough for 11). The lysis mixture consists of PCR lysis buffer 
and Proteinase K 1/500 dilution. Add 30 µl of this lysis buffer mixture to each tube. Place 
tube in PCR machine and incubate at 55ºC for 1 h .Vortex halfway through the incubation to 
facilitate lysis. Incubate at 95ºC for 5 min to de-activate proteinase K. Add 30 µl of distilled 
water and vortex for 30 s. Spin at 12,000 rpm for 1 min. Use 1 µl of supernatant per PCR 
reaction. Store the DNA sample at -20ºC. 
PCR Lysis Buffer (stored at -20ºC) 10X GB, 25% TritonX-100, beta-mercaptoethanol, H2O10X 
GB (store at -20ºC) 1.5M Tris pH8.8, 1.0M (NH4)2SO4, 1.0 M MgCl2, H2O 
 
5.8 Mouse  Total RNA Master Panel  
 
Mouse total RNA master Panel (Clontech 636644 see Appendix AP1.11). Total RNA from 
BALB /c m/f mice isolated by a modified guanidinium thiocyanate method. Total RNA from 
15 different samples of tissue and developmental stage specific RNA with a concentration of 
1ug/ul. Total RNA is transcribed into cDNA with SuperScript (see 5.5) and cDNA is used as a 
template for PCR with proofreading DNA Polymerases Phusion (see 5.3.7). Additionally one 
sample of black6 mice DRG cDNA (Black6 DRG) =110ng/ul is added to the mouse Total RNA 
master panel. 
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Primers for mouse tissue panel are chosen due to their efficiency in previous PCR reactions. 
Neat template is diluted ¼ in H20. 
 
Nav1.7 sense primers M1.7 RXN 6 FWD 5’-GGCAAACTGACTACATGAGTTTTG-3’, M1.7 RXN 6 
REV5-‘TGTAAACAGTGTATCAAAACCGAAGC-3’expected size 1375bp, which were also used 
during the RNA editing project. Nav1.7 antisense primer: M1.7 AS 1 FWD 5’- 
GAACCAGGTCTTGCTTTTCG, M1.7 AS 1 REV5’CCACGCTTTGTTCCTAGAGC-‘3 expected size 
625bp. Housekeeping Gene HPRT1: FWD 5’- GATGATGAACCAGGTTATGACC-3’, REV 5 –
TTTCCAGTTTCACTAATGACAC-3’ expected size 605bp  
PCR reactions were performed with proofreading DNA polymerases – i.e. Phusion (see 
5.3.7) 
ThermoCycling condition: Annealing temperature (Ta)  
Ta (M1.7RXN 6) =63.3 C, 35 cycles; Ta (M1.7 AS 1) =63.5 C, 30 cycles; Ta (HPRT1) =55C 
30 cycles; PCR with Phusion is performed at an annealing temperature +3C above the Tm of 
the primer used during PCR. 
 
5.9 VECTORS 
 5.9.1A Cloning of human full length antisense transcript  
 
Human, BC051759, cloning of the whole BC051759 sequence from a bought cDNA: IMAGE 
Human CDNA clone, BC051759 Clone ID 5582690. CDNA Image Human Clone arrived in a 
glycerol stock and was plated out onto LB Amp plates. Following incubation overnight, single 
colonies were inoculated into 5ml liquid LB + Ampicillin. DNA was then isolated using 
Miniprep protocol and used as template in PCR using Phusion. To obtain enough antisense 
transcript for cloning into pcDNA3 expression vector, at least 8 identical PCR reactions were 
started. Primer: Human AS HINDIII FWD 5’-CCCAAGCTTGTCTTAGTCCTCTGAATATTTT-3’, 
Human AS KpnI REV5’-CGG GGTACC CCA ATTGATGGAGAATTTTAT-3’ expected size of the 
PCR product 2302bp. 
PCR reactions were loaded on a 0.9% agarosis gel and bands cut out under UV and pooled 
for gel purification. Human Nav1.7 full length antisense sample concentration measured via 
Nanodrop: c (H1.7AS): 98.4 ng /ul eluted in 40 ul Elution Buffer (Qiagen) (used as stock). 
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Fig 5.9a Human (A) Amplification of full length antisense sequence from a cDNA clone using specific 
primers with integrated restriction sites (B) Double restriction digest with KpnI and HindIII 
 
5.9.1B Cloning of mouse full length antisense transcript   
 
The mouse full length antisense transcript was cloned using a mouse cDNA clone as 
template (AK138532) (Fantom CDNA clone 
(http://www.dnaform.jp/products/fantom/pdAf/FANTOM-PX-PY-PZ.pdf) (see Appendix 
AP1.12). The cDNA clone stock (5 ng) was plated out onto LB+AMP plates and incubated o/n 
at 37 degrees. The following day, single colonies were inoculated into 5ml liquid LB + 
Ampicillin. DNA was then prepared using a Miniprep protocol and used as template in PCR 
using the Phusion proofreading DNA polymerase. To obtain enough antisense transcript for 
the following cloning step into pcDNA3, at least 8 identical PCR reactions were performed 
using the proofreading DNA Polymerase Phusion. Primer sequences: Mouse full- length 
antisense HindIII FWD 5’-CCCAAGCTT GAGCAAGAGT AAGAAGTA-3’, Ms AS KpnI REV 5’- CGG 
GGTACC GCCATTATATTTCAT-3’, expected size 1347bp (full length antisense cDNA sequence 
see supplemental data 2). PCR reactions were loaded onto a 0.9% agarosis gel and bands 
were cut out under UV and pooled for gel purification. Mouse Nav1.7 full length antisense 
sample concentration measured via Nanodrop: (Ms Nav1.7): 46.5 ng /ul eluted in 40 ul 
Elution Buffer (Qiagen)  
 
For Both 5.9.1A and 5.9.1B  
A B 
Exp Vector 
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As the human and mouse full length antisense transcripts are non-coding and not translated 
into protein, precise cloning of the antisense transcript with as few as possible additional 
bases is required. Therefore human and Mouse full length antisense primers are designed to 
include specific restriction sites that map to the 5’ end of the multiple cloning site to reduce 
the number of additional bases that could be transcribed from the pcDNA3 expression 
vector. Restrictions sites integrated into the primer sequence were chosen according to 
RestrictionMapper (http://www.restrictionmapper.org/). Browsing of both human and 
mouse SCN9A antisense transcript cDNA gave KpnI and HindIII as optimal cutters as they do 
not cut within the antisense transcripts but have cutting sites towards the 5’ end of the 
multiple cloning site ofpcDNA3. 
 
 
 
 
 
 
 
 
 
 
 
Fig5.9b Mouse (A) Amplification of full length antisense sequence from cDNA clone using specific 
primer with integrated restriction sites .Clear and strong band are visible on the gel  
 
5.9.2 Expression vector  
 
pcDNA3 (Invitrogen see appendix), empty vector size 5.4kb, sample concentration 2ng / ul 
(Fig 5.9c) with multiple cloning sites (for full description see appendix AP 1.13). Both 
pcDNA3vector and full length human/mouse Nav1.7 antisense transcript are double 
digested O/N at 37 degrees with KpnI and HindIII. Double digest conditions for HindIII and 
KpnI are chosen according to http://www.neb.com/nebecomm/DoubleDigestCalculator.asp 
for Double Digest Finder. 
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Digestion for 3 hours at 37 degrees in H20, Buffer NEB 2, BSA for optimal digesting 
conditions. To verify that the double digest was successful, both the vector and the 
antisense samples are loaded on a 0.9% agarosis gel and cut out under UV.  
Concentrations human H.1.7 AS = 43.8ng /ul and Vec 1 = 110.5ng/ul 
.   
 
       
Fig 5.9c pcDNA3 Vector with MCS (multiple 
cloning sites) and full length human /mouse 
Nav1.7 antisense cDNA integrated between 
HindIII and KpnI. Full length Nav1.7 antisense 
transcript mouse: 1380bp, cDNA full length 
Nav1.7 antisense transcript human: 2302bp 
 
 
 
 
 
 
Nav1.7 antisense transcript human/mouse is gel purified and has the final concentration 
after gel purification:  Vec2 =131.4ng /ul; Mouse Ms1.7 AS =16.9ng/ul and Vec1 =119.3ng 
/ul, Vec2 =102.5ng/ul 
 
5.9.2.2     SAP TREATMENT OF pcDNA3 ONLY  
Linearized pcDNA3 Vector is treated with SAP (see Appendix AP 1.14).  
10ul Vector / 0.5 ul SAP  incubation for 40 min at 37 degrees and 20 min for 72 degrees. 
 
5.9.2.3    Ligation of full length NAV1.7 antisense transcript to pcDNA3 vector.  
Equation to determine best vector: insert ratio for ligation. 
 
Vector (ng)       x     insert size (kb)        x   3: 1 or 5:1 ratio 
Size of vector (kb) 
 Full length cDNA human/mouse antisense transcript  
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Table 1: Ligation approaches human Nav1.7 antisense expression vector  
 
Ratio Vector (Vec2) Insert(44ng/ul) H20 
5:1 
3:1 
1:1 
10ng(0.76ul) 
10ng(0.76ul) 
10ng(0.76ul) 
50ng(4.84ul) 
30ng(2.90ul) 
10ng(0.97ul) 
Up to 17 ul 
Up to 17 ul 
Up to 17 ul 
Plus ligase 10ng(0.76ul) x Up to 17ul 
No ligase 10ng(0.76ul) x Up to 17ul 
Neg control x x Up to 17ul 
 
Table 2: Ligation approaches mouse Nav1.7 antisense expression vector 
Ratio Vector (Vec2) Insert(16.9ng/ul) H20 
5:1 
3:1 
1:1 
10ng(0.83ul) 
10ng(0.83ul) 
10ng(0.83ul) 
50ng(7.52ul) 
30ng(4.51ul) 
10ng(0.70ul) 
Up to 17 ul 
Up to 17 ul 
Up to 17 ul 
Plus ligase 10ng(0.83ul) x Up to 17ul 
No ligase 10ng(0.83ul) x Up to 17ul 
Neg control x x Up to 17ul 
 
Ad table 1 and 2: control reactions (1) Plus ligases was used as background control 
(2) No ligases determine the degree of undigested vector pcDNA3 (3) negative control with H20 
instead of insert determines general contamination 
 
• Ligation Mix: T4 Ligase (Fermentas), T4 ligase Buffer (Fermentas), H20. Ligation 
Master Mix is added, followed by 1 hour incubation at 22 degrees.  At this point 
reactions can be stored at – 20 degrees. 
 
5.9.2.4 Transformation of human/mouse antisense ligations into chemically competent 
E.coli cells    
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Transformations were plated out onto LB/Agar + Amp plates and incubated O/N at 37 
degrees. Transformation protocol for see XL10 – Gold ultracompetent cells. 
On the water negative control plates no colonies were visible. A few colonies appeared on 
the plates with “no Ligases” and “plus Ligases “. Ten single colonies were picked from 
positive 3:1, 5:1 plates and inoculated into 5 ml LB+Amp and incubated O/N shaking at 220 
rpm at 37C. The bacterial cells were harvested by centrifugation at 5000 rpm for 10 min, 
and supernatant was discarded while the pellet contains the amplified expression vector. 
This step is followed by Miniprep and double restriction digests (Fig 5.9.a) with HindIII and 
KpnI to check for positive colonies that have inserted the full length antisense transcript into 
the vector. 
Gel purification (see 5.3.5) of the positively transformed samples. As our gene of interest 
was already positively inserted into the vector, 2 chosen samples were re – transformed into  
XL-10 Gold ultracompetent cells  (Invitrogen, see 5.3.1) and plated on LB+Amp plates and 
incubated O/N at 37 C. Single colonies from the LB+Amp plates  were brought into a 5 ml LB 
+amp day culture, and let to grow shaking 250rpm for approximately 7 h at 37 C. Day 
cultures were then transferred into Maxiprep cultures, 500 ml LB +amp, incubated O/N, 
shaking at 250 rpm at 37 C and then Maxiprepped (Qiagen, high speed Maxiprep see 5.3.4).  
DNA was eluted in 1ml Elution Buffer EB and concentrations measured using Nanodrop: 
Human (EXPH1) = 413 ng /ul; Human (EXPH2) = 345 ng/ul; Mouse (EXPM1) = 204 ng/ul; 
Mouse (EXPM2) = 276.3 ng/ul 
To ascertain that there were no rearrangements or deletions of the full length (A) human (B) 
mouse full length SCN9A antisense transcript vectors, double digest with KpnI and HindIII 
was performed (Fig 5.9e). 5 ul of each samples were loaded onto 0.9% agarosis gels.  
 
A B 
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Fig 5.9e Double Digest with KpnI and HindIII after Maxiprep to check that the expression vector 
constructs have positively integrated our insert of interest (A) human (B) mouse full length SCN9A 
antisense transcript. 
 
Samples that contain the full length human/mouse antisense transcript according to the 
right size on the analytical gel are diluted in EB to a concentration of 110ng/ul for 
sequencing with primers (for mouse (see mouse antisense primers 5.10.1.3) and for human 
(see human antisense primer 5.10.2.3)). Primers are chosen and designed to give partially 
overlapping sequences of full length human/mouse SCN9A antisense transcript. 
 
5.9.2.5  Sequencing - Bioinformatics  
 
Sequencing results of each partial sequence were individually compared against reference 
sequence databases using the Genome UCSC (http://genome.ucsc.edu/) and NCBI BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) web tools. Nucleotide blast (Data base: Reference 
genomic sequences (refseq_genome), organism: mus musculus taxid: 10090 or Homo 
sapiens taxid: 9606) identified the sequenced inserts as full length human BC051759 and 
mouse AK138532 full length SCN9A antisense transcripts. Expression vectors are stored at -
20C. 
 
5.9.3    Additional vectors: pEGFP  
 
pEGFP vector has the size of ~ 3.4kb and encodes for a red shifted variant of a wild type GFP 
(AP 5.9.4), GFPmut1 with an excitation maximum at 448 nm and emission maximum at 507 
nm(Fig 5.9f ). For full information on pEGFP vector with MCS and additional features see 
Appendix AP1.15 (or http://www.pkclab.org/PKC/vector/pEGFPN1.pdf) 
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Fig 5.9f (A) EGFP vector with and restriction map and MCS 
 
5.10           Primer mouse Nav1.7 sense and  antisense transcript    
5.10.1.1 Primer mouse Nav1.7 Antisense transcript  
 
M1.7 AS1 FWD 5’- GAACCAGGTCTTGCTTTTCG -3’, REV 5-‘CCACGCTTTCCTAGAGC-3’ 
Size 625bp; 
M1.7 AS2 FWD 5-‘GGAAGGGACATCATCAGAGC-3’ REV 5-
‘TCATTTTAATGAATCAAGCCTTA-3’ size 908 bp  
M1.7 AS3 FWD 5’-GATCAGGCGTAGGATTCGTC-3’, REV 5’-CATAGACACTGCGTGCTGCT-
3’, size 624bp 
M1.7 AS4 FWD 5’- GCACGACTTCTCCTGCTGC-3’, REV 5’-CARAGACACTGCGTGCTGCT-
3’ size 879bp 
 
5.10.1.2   Full length SCN9A antisense transcript  
Name Sequence 5’-3’         Size Tm 
MS HindII FWD CCCAAGCTT GAGCAAGAGT AAGAAGTA     1347bp 61.4 
MS KpnI REV CGG GGTACC GCCATTATATTTCAT  
 
5.10.1.3          SCN9A sense - sequencing 
A 
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Name  Sequence  5’- 3’ Size Tm 
Runs from  
M1.7 RXN 1 FWD 
NM_018852  500 – 1504  
CTCTTAGGTAAGGATCCGAAGGGG 
  
1004 bp              69 
M1.7 RXN 1 REV GAAACCGCAAAGAAGAGCATCTTG   
Coding sequence 
M1.7 RXN 2 FWD 
M1.7 RXN 2REV 
NM_018852  1365-2616 
ATAAATGTTTCCGGAAGGACCTTG 
ACTGTGTTGGTTAGAATGCTTGCTC 
 
                   1251 bp 
 
        68 
Coding sequence 
M1.7 RXN 3 FWD 
NM_018852 2447-3657 
GGACCCTCAGCCCTCATGCTC 
 
                   1210 bp             
 
 72 
M1.7 RXN 3 REV CTTATCTCCGCAAGGGTACGGTTTG   
Runs from  
M1.7 RXN 4 FWD 
NM_018852  
TCCAAAAAGCCAAAGGGCTCCA 
     
                   1096 bp     
 
67 
M1.7 RXN 4 REV GCACATTTCCACTAACATTCATCAG   
Runs from  
M1.7 RXN 5 FWD 
NM_018852 
TGTGTTAACACCACAGATGGCTC 
 
                 701 bp 
 
69 
M1.7 RXN5  REV AAATCAAAAATGTTCCATCCCACG   
Runs from 
M1.7 RXN 6 FWD 
M1.7 RXN 6 REV 
NM_018852 
GGCAAACTGACTACATGAGTTTTG 
TGTAAACAGTGTATCAAAACCGGC 
 
                   1375 bp 
 
65 
 
5.10.1.4      Additional   Sequencing Primer  
T7 5’- TAATACGACTCACTATAGGG-3’, SP6 5’-TACGATTTAGGTGACACTATAG-3’ 
 
5.10.1.5         Mouse tissue panel  
 
Sense: M1.7 RXN 6 FWD 5’-GGCAAACTGACTACATGAGTTTTG-3’, 
 M1.7 RXN 6 REV 5-‘TGTAAACAGTGTATCAAAACCGAAGC-3’ 
Antisense: M1.7 AS 1 FWD 5’- GAACCAGGTCTTGCTTTTCG,  
M1.7 AS 1 REV 5’CCACGCTTTGTTCCTAGAGC-‘3 
Housekeeping gene HPRT 1: FWD 5’- GATGATGAACCAGGTTATGACC-3’,  
REV 5’ –TTTCCAGTTTCACTAATGACAC-3’ 
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5.10.2              Primer human Nav1.7 sense and  antisense transcript  
5.10.2.  1 Primer Human BC051759 antisense transcript: full list  
   
H 1.7 antisense 1 FWD 5’-GGAATTCAGGCAAAGTTGGA-3’, H 1.7 antisense 1 REV 5’-
CACCAACATTCAGCCATTTG-3 size 991bp 
H 1.7 antisense 2 FWD 5’-GGATCACTCGGAACAGGGTA-3’ , H 1.7 antisense 2 REV  5’-
CACCAACATTCAGCCATTTG-3’size 819bp 
H1.7 Primer set 1 FWD 5’- CACCAGCGACAAAGAAGTCA-3’, H1.7 Primer set 1 REV 5’-
AGGGAGTGACGCACAAAAAC-3’ size 1572 
H1.7 Primer set 2 FWD 5-‘GCCTCAAGTGATCCTTCTGC-3’, H1.7 Primer set 2 REV 5’-
TTTTCTCACTGGGATCTGTCC-3’ size 2000bp 
H1.7Primer set 3 FWD 5’-GTGGGAGCGTACAGTCATCA-3’, H1.7Primer set 3 REV 5’-
AGGGAGTGACGCACAAAAAC-3’ size 1017   
 
5.10.2.2 Full length SCN9A antisense transcript 
Name Sequence       Size     Tm 
Hm HindIII  FWD CCCAAGCTTGTCTTAGTCCTCTGAATATTTT       2302bp      58.5  
Hm KpnI    REV CGGGGTACCCCAATTGATGGAGAATTTTAT  
 
5.10.2.3  Sequencing primer  
T7 5’- TAATACGACTCACTATAGGG-3’, SP6 5’-TACGATTTAGGTGACACTATAG-3’ 
  BC05179XX FWD 5’-GACTTTTGGAGTAATCATGGAA-3’ 
  
5.11 Cell culture 
 
All cell culture work (e.g. cell splitting, media preparation, transfections and coverslip 
coating) are performed under a previous EtOH sterilized hood to ensure maximum sterility. 
Lab coat and gloves sterilized with EtOH must be worn at all times. 
 
5.11.1 Cell Lines  
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HEK 293 cells that stably express Nav1.7 were generated by stable co transfection of HEK 
293 cells with an alpha subunit and a beta1 subunit of human sodium channel 1.7 (Scottish 
Biomedical). 
HEK 293 Nav1.6 L40 cell line was generated by stable co transfection of HEK 293 cells with 
an alpha subunit and a beta1 subunit of human sodium channel 1.6 (Scottish Biomedical). 
 
5.11.2  Cell culture media – MG 
 
MEM (Sigma M5650), 2mM L- Glutamine (Sigma G7513), 10% FBS Heat inactivated 
(Invitrogen 2011-11), 2ug/ml Blastocydin (calbiochem 203350), 0.6mg/ml Geneticin 
(Invitrogen 10131-027), 10ml/L Penicillin –streptomycin (Sigma P0781). All reagents were 
filtered under the lamina through Stericup/Steritop filter (Millipore) to avoid contamination. 
 
5.11.3  Cell splitting  
 
Aspirate media and incubate with trypsin for ~2-3 minutes. Aspirate trypsin and resuspend 
in 10 ml of culture media MG Nav1.7 stable and wash off the cells. Transfer suspension into 
15ml tubes and centrifuge 5 min at 800rpm. Aspirate supernatant and resuspend cell pellet 
in 10 ml MG stable cell media. Cells are split into 2ml dishes or a flask. Best transfection 
results are obtained with cells at around 90 per cent confluence on the day of transfection.  
 
5.11.4  Coating  
 
Both BD Matrigel (BD Biosciences) and DMEM (Sigma M5650) need to be permanently kept 
on ice. 200ul Matrigel is added to 20ml filtered DMEM without FBS (Invitrogen 2011-11). 
After gently mixing the reaction 300ul of the mixture is added to coverslips in a 24 well plate 
and incubated for 30 minutes at RT. Aspirate excessive Matrigel and replace with 500 ul cell 
suspension, placed onto each coated coverslip/well. 
 
5.11.5  Transfection 
5.11.5.1 Transfection of Nav1.7 stable expressing cell line for immunohistochemistry 
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Nav1.7 cells with an approximately 90% confluence were transfected with (1) no DNA (2) 
EXPH1, pcDNA3 vector containing full length human SCN9A antisense transcript  
Concentration: (EXPH1) = 413 ng /ul; According to the manufacturer’s protocol, DNA was 
mixed with Lipofectamin in a 1:2.5 ratio.  
 
Transfection solution was slowly and drop wise added to the Nav1.7 cells and incubated for 
6 h at 37C /5% C02. After 6h the transfection solution was aspirated and replaced with MG 
stable cell culture medium (see 5.11.2). Cells were incubated at 37C / 5 % CO2 for 24hr.  
 
5.11.5.1.1  Immunohistochemistry 
 
MG stable medium is firstly aspirated. Gently add ice cold methanol to each well and put 
well plate for 5 minutes into the -20 C freezer. 
Have ice cold acetone in a glass bottle ready. Coverslips are dipped shortly into ice cold 
acetone and left to air dry on paper. Remaining coverslips which are not used for further 
analysis can be stored at -20C. Add 3% BSA blocking solution in 1x PBS for at least 45 
minutes at room temperature. Aspirate off blocking solution. Prepare a 1/500 dilution of 
N68/6 Monoclonal mouse anti-Nav1.7 in 3% blocking solution. Add 250 ul to each coverslip 
and incubate for at least 1 h at room temperature. Wash three times with blocking solution. 
Add 1/1000 dilution of secondary antibodies in blocking solution (Invitrogen A11032 – 594 
goat anti-mouse). Add 250 ul to each coverslip (except 1 one coverslip and incubation for 1 
h at room temperature). Remember to include no primary antibody and no secondary 
antibody controls. Wash coverslips two times with blocking solution and two times with 
PBS.  Finally add a 1/5000 dilution of DAPI/ PBS for nucleus staining. 250 ul of DAPI/PBS 
solution per well are added and incubated for 5 minutes at room temperature. Washing 
steps: three times with PBS, one time in ultra-pure sterile water. Mount cells with ProLong 
Gold antifade reagent and let coverslips mounted to glass slides dry on the slides overnight 
at 4 degrees. Coverslip edges are sealed with nail varnish before microscopy. Store slides at 
-20C. 
 
5.11.5.2 Transfection of Nav1.7and Nav1.6 stable cell line for patch clamp  
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Cell lines  stably expressing  Nav1.6 or  Nav.1.7(see 5.11.1)  are split into 2ml dishes and 
were grown to 90% confluence for transfection with (A) no DNA as a negative control to 
check for any contamination of either Lipofectamine 2000 (Invitrogen), Optimem (Invitrogen  
11058-021)., (B) pEGFP-N1(see 5.9.3), to determine transfection efficiency and (C) EXPH1 
,expression vector pcDNA3 containing human full length Nav1.7 antisense transcript 
BC051759 ( see section expression vector design 5.9.1A  – 5.9.2.5 ) and (D) EXPH1 co 
transfection with pEGFP-N1 to detect transfected cells assuming that cells that take up the 
expression vector  also take up pEGFP- N1. (E) Empty pcDNA3 vector as transcriptional 
control. 
Vector concentration: (pEGFP-N1) =308ng/ul; (EXPH1) =413 ng/ul; (pcDNA3) = 2mg /ul.  
To obtain comparable results from each transfection for approached A – E an equal amount 
of DNA was used for transfection of the stably expressing Nav1.6 and Nav1.7 cell lines 
Highest transfection efficacy was experimentally found at a DNA: Lipo2000 ratio of 1:2.5. 
 
Table 2 Overview of transfection approaches (patch clamp) 
A. Reagent No DNA EGFP-N1 EXPH1 EGFP-N1+ EXPH1 pcDNA3 
Lipo2000(ul) 3.125 0.625 2.5 3.125 2.5 
Optimem (ul)  250 250 250 250 250 
B.DNA used      
concentration No DNA 308ng/ul 413ng/ul 308/413ng/ul 2mg/ul 
in ul No DNA 0.81 2.42 0.81/2.42 0.5 
in mg No DNA 250 1000 250/1000 1000 
 
Add Table 2 Overview of transfection approaches: gives a schematic overview of each 
performed transfection approach with reagents, concentrations, volumes and ratios used for 
each transfection approach. EXPH1 (see expression vector 5.9.2), pcDNA3 vector that has 
full length antisense transcript integrated .EGFP-N1, green fluorescence protein (see 5.9.3) to 
evaluate transfection efficiency. 
 
Following transfection, cells are split to <50% confluence so that single cells can be analysed 
by patch clamping two days after transfection 
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6. Results SCN9A and its corresponding antisense transcript 
6.1. Bioinformatics 
 
By browsing the human and mouse genomes for SCN9A, several ESTs are found on the 
GENOME UCSC browser (http://genome.ucsc.edu/) which are partially complementary to 
the SCN9A gene. SCN9A encodes for a voltage gated sodium channel which is predominantly 
found in DRG and sympathetic ganglion neurons. 
In search for the human antisense gene, several expressed sequence tags (ESTs) (BC051759, 
BC029452, BM905527, BE566126, BG215777, AA383040) were found which suggested a 
cDNA/mRNA comprised of at least 12 exons, four of which are complementary overlapping 
the SCN9A sense exons encoded on chromosome 2. The longest human EST is BC051759. 
For all ESTs, five of their exons are associated with Alu’s, SINEs, and LINEs. The final exon has 
a polyadenylation signal and the first exon is not associated with a CpG island. For the 
mouse antisense gene, we identified the following antisense ESTs AK039017 (hypothalamus 
cDNA), AK045660 (corpora quadrigemina cDNA), AK020721 (hypothalamus cDNA), 
AK138511 (spinal cord) and AK138532 (spinal cord). Two of these ESTs are from the spinal 
cord where SCN9A is known to be expressed and suggests a cDNA comprised of 5/6 exons.  
Bioinformatics comparison of the human and mouse antisense gene shows one of the exons 
is highly conserved between human and mouse and this maps to the final exon of the sense 
SCN9A gene.  
To prove that the antisense gene exists and is not only an artefact, we screened for its 
expression in DRG neurons with mouse and human antisense specific primers. Mouse 
SCN9A antisense primers (See 5.10) M1.7 AS 1 FWD, M1.7 AS 1 REV expected size 625bp, 
M1.7 AS 3 FWD 5’- , M1.7 AS 3 REV expected size 626bp. Human SCN9A antisense Primer 
H1.7 AS FWD 5’-GGAATTCAGGCAAAGTTGGA-‘3, H1.7 AS REV 5-CACCAACATTCAGCCATTTG-
‘3 with expected size of 991bp. DRG RNA was freshly prepared from black 6 mice and 
human DRG total RNA was purchased from Clontech. These DRG RNA samples were reverse-
transcribed into cDNA and used as PCR templates. 
Strong and clear bands for the human and mouse Nav1.7 antisense transcript appear on the 
agarosis gel suggesting that the SCN9A corresponding antisense transcript is not an artefact 
but a real transcript that is expressed in dorsal root ganglia. To further verify that the bands 
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for human and mouse Nav1.7 antisense transcript were as expected, the bands were cut 
out, gel purified and DNA sequenced.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig6. 1(A) Clear and strong bands for M1 and M3 and (B) H1 and H3 suggest there is an 
antisense transcript expressed in mouse and human DRG neurons. 
 
 
The primers which are used for sequencing are identical to the ones used for Phusion PCR 
reaction Mouse Nav1.7 AS 1 and 3, and Human Nav1.7 AS 1 and 3. 
NCBI Blast  (http://blast.ncbi.nlm.nih.gov/Blast.cgi) of human and mouse sequencing data 
against the whole genome gave a 100 per cent sequence ID of the human sequence data H1 
and H3  to the human BC051759 antisense transcript  and the mouse sequencing data M1 
and M3 to the mouse AK138532  antisense transcript (supplemental data 2). 
 
M1 M3 
random Oligo d(T) 
M1 M3  M4 
H1 H3 H3 H1 
random Oligo d(T) 
A 
B 
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6.2   Mouse tissue panel 
 
To test whether the sense and antisense transcripts are co expressed in different tissues, an 
RT-PCR using a mouse total RNA panel was performed. 15 different tissue specific RNA 
samples from the Clontech kit and one sample of freshly isolated DRG RNA were reverse-
transcribed into cDNA with Superscript II and used as PCR templates with HPRT1, SCN9A 
sense and antisense specific primers. HPRT1 is a house keeping gene that is involved in the 
purine salvage pathways and was used as a reference PCR (56). HPRT1 is constantly and 
almost equally expressed in all tissue samples tested, confirming that reverse transcription 
was consistent and successful across all tissues. Furthermore, sequencing results verified 
that our specific primers correctly amplified the SCN9A and AK138532 antisense gene in the 
given gels. The agarosis gels show that SCN9A is highly expressed in DRG, brain, eye, smooth 
muscle and spinal cord samples. These findings are identical with the prior Microarray 
expression pattern Data for Mouse (GNF Expression Atlas 2 Data from GNF1M Mouse Chip, 
GENOME USCS). Although SCN9A is mainly found in the peripheral DRG neurons, it is also 
weakly expressed in the CNS. The microarray data also evaluates which brain tissue 
particularly expresses SCN9A: Hypothalamus and weak expression in the substantia nigra 
and the frontal cortex. (MICROARRAY, GENOME USCS) 
 
Interestingly, SCN9A antisense transcript is mainly found in the brain, spinal cord, DRG and 
eye samples, with highest expression in the brain and spinal cord. In contrast to the SCN9A 
sense gene, the antisense gene is not detectable during any developmental stage or in 
smooth muscle tissue. Several studies have reported an important role for Nav1.7 in 
cultured human smooth muscle cells such as coronary arterial, pulmonary arterial and 
bronchial smooth muscle cells but not freshly isolated rabbit (58) aortic smooth muscle cells 
and human pulmonary artery smooth muscles (59).However, in brain, DRG, eye and spinal 
cord tissue samples, both sense and antisense transcripts co- expression was detected. 
Although it is very tempting to make an assumption about the expression level of sense and 
antisense gene in the used tissue samples due to variation in band intensity the expression 
levels needs to be fully evaluated by quantitative RT- PCR and protein levels assessed by 
western blotting. Nevertheless, this semi-quantitative result highlights that the sense and 
antisense transcripts are expressed in a broadly similar tissue expression pattern. 
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Sense and antisense specific PCR showed a significantly different expression pattern during 
development stages D7, D11 and D15. While the SCN9A sense gene is expressed during D11 
and D15, SCN9A antisense transcript is not amplified from the D7 to D15 samples. It has 
been reported that the SCN9A sense gene has different splicing variants, one of which is 
neonatal (57). Exon 5 is alternatively spliced in SCN9A and its neonatal splicing variant has 
significantly different electrophysiological properties. The exact purpose of a neonatal 
splicing variant is yet not fully known. However, the complete absence of antisense 
transcript during the developmental stage D7 to D15 gives rise to the idea that the antisense 
transcript might shift the splicing event in favour of one transcript rather than the other. 
The proposed mechanism is that expression of the antisense transcript stabiles the adult 
transcript, or binding masks the splicing site of the primary mRNA and therefore represses 
the neonatal splicing variant in favour of the adult one. The SCN9A sense primers were not 
specifically designed to detect a certain splice variant and unfortunately the bands 
appearing on the gel for the early developmental stages were not sequenced. Therefore 
there is no evidence that the bands on the gel are the neonatal splice variant. A different 
explanation for the absence of SCN9A antisense transcript in D7, D11 and D15 could be that 
SCN9A antisense transcript is only found in adult mice and has nothing to do with neonatal 
splicing variant or the antisense transcript was simply not detectable on the gel due to its 
low expression level. 
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fig X Mouse tissue panel for (A) Housekeeping gene  (B) SCN9A sense and  (C) SCN9A 
antisense gene. HPRT 1, a housekeeping gene, is expressed in all tissues and in all 
developmental stages tested .There is a spatial and temporal difference in the Nav1.7 sense 
and antisense transcript expression pattern. In particular the mouse Nav1.7 antisense 
transcript is strongly expressed in the Brain, Eye, DRG neurons and spinal cord but seems not 
to be expressed during the early developmental stages D-7,-11 and D-15. In comparison 
Nav1.7 is expressed even during early development and is also found in brain, eye and spinal 
cord but as to be expected mainly in DRG neuron. 
 
C.SCN9A Antisense  
B. SCN9A 
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6.3   Immunohistochemistry  
 
Transfection of Nav1.7 stable cell line with SCN9A antisense transcript  
 
We decided to investigate the effect of overexpressing the human antisense gene in a 
HEK293 stable Nav1.7 cell line. The effect of overexpressing the antisense transcript in this 
cell line was tested by immunohistochemistry (to semi-quantatively assess SCN9A protein 
levels) and by patch clamping (to study the effect on Nav1.7 sodium currents). 
An expression vector containing the human antisense transcript (BC051759) was cloned and 
transfected into the HEK293 Nav1.7 stable cells, along with an empty GFP vector to mark 
positively transfected cells line (see transfection protocol 5.11.5.1). 
It is assumed that cells that take up pEGFP are also taking up EXPH1 (the antisense 
construct).  
 
One day after transfection the cells were fixed with methanol and stained with an anti-
Nav1.7 antibody. Figures A-C and D-F show two fields of vision in which the antisense 
transcript was co-expressed with a GFP expression vector. Fig A and D show cells positively 
transfected with the GFP construct (and which also are likely to express the antisense 
transcript). Figs B and E show Nav1.7 protein stained in red. Fig C and F show nuclei stained 
with DAPI. The results show that cells which express GFP and the antisense construct are 
still stained with the anti-Nav1.7 antibody. There is therefore no obvious effect of 
overexpressing the antisense transcript on Nav1.7 protein levels. However, it must be noted 
that this is a cell line which itself artificially overexpresses Nav1.7, and the effect on protein 
levels of overexpressing the antisense transcript should be tested in cells which 
endogenously express Nav1.7 (such as DRG neurons) and also by a more quantitative 
technique. 
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Fig A- F Immunohistochemistry. HEK293 cells stably expressing Nav1.7 are co-transfected 
with a pcDNA3 vector containing SCN9A antisense transcript and a GFP vector and 
monitored 24h after transfection.  
A and D: Cells positively transfected with pEGFP (and most likely the antisense construct) are 
shown in green. B and E:  N68/6 monoclonal mouse anti-Nav1.7 antibody (Millipore) is used 
to detect the expression of Nav1.7 (in red) C and F: DAPI staining. DAPI (4', 6-diamidino-2-
phenylindole) can pass the membrane and binds to AT rich DNA region. 
 
6.4  Electrophysiology  
 
To functionally test the overexpression of the human Nav1.7 antisense transcript on sodium 
currents, cells stably expressing either Nav1.7 or Nav1.6 were transfected with  
 (1) EXPH1 and pEGFP-N1 or (2) empty pcDNA3 and pEGFP-N1. Two days after transfection 
the cells were patch clamped (John Linley, Post-Doc, Molecular Nociception Group, London 
A B C 
D E F 
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The results show that overexpression of the Nav1.7 antisense transcript in a cell line that 
stably expresses Nav1.7 results in a statistically significant reduction in the peak sodium 
current. In Nav1.6 stably expressing cells, overexpression of the Nav1.7 antisense construct 
has no effect on the sodium current. This shows that the Nav1.7 antisense transcript is 
specifically targeting Nav1.7. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig Overexpression of human Nav1.7 antisense inhibits Nav1.7 but not Nav1.6 currents.  
Whole cell voltage clamp recording from HEK cells stably expressing human Nav1.7 or 
human Nav1.6. Cells were transiently transfected with either pCDNA3 vector or Nav1.7 
antisense and recorded from 48hrs later. Peak whole cell current (pA) was measured in 
response to a 10 Ms voltage step from the holding potential of -120 mV to 0 mV and 
normalised to cell size (pF). N = 17- 20; * indicates p<0.05 when compared to control (un-
paired t-test). 
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7. Discussion  
 
Through analyses of genome browsers and using RT-PCR of dorsal root ganglia cDNA, we 
have identified and cloned a SCN9A natural antisense transcript (NAT) that exists in both the 
human and mouse genomes. The human NAT is comprised of at least 12 exons, 4 of which 
partially overlap SCN9A sense exons and is polyadenylated. The mouse NAT is comprised of 
at least 6 exons, one of which is conserved with the human NAT and overlaps the final sense 
SCN9A coding exon, and is also polyadenylated. The human and mouse NATs are arranged 
in a tail-to-tail configuration with the sense genes. 
 
Expression analysis using RT-PCR of a commercially available mouse RNA tissue panel show 
that the Scn9a  sense and antisense genes are expressed in broadly similar tissues (e.g. DRG, 
spinal cord, brain and eye). This is important because the NAT may regulate sense 
mRNA/protein levels in tissues in which it is co-expressed with the sense gene. It is known 
that antisense genes can regulate the level of sense transcript through activation of the 
RNAi pathway. Here, RNAi could subsequently lead to a down regulation of functional 
Nav1.7 channels and therefore induce a shift in neuronal excitability due to absence of 
functional Nav1.7 sodium channels.  In RNA masking, antisense-sense transcript 
hybridization might mask important ribosomal binding sites leading to a reduction in 
translated protein. A third possible way of how the NAT might disrupt the function of the 
sense gene is through transcriptional collision. To further investigate this mechanism, the 
NAT promoter should be characterised and the temporal correlation between sense and 
antisense transcription should be assessed in a cell line that endogenously expresses 
Nav1.7. The human Nav1.7 stable cell line has the clear disadvantage that Nav1.7 is 
ectopically expressed in these HEK cells and differs strongly in its physiological expression 
that is found in DRG neurons. 
 
By overexpressing the human NAT in a cell line that stably expresses Nav1.7, we have shown 
that the NAT negatively regulates the SCN9A sense mRNA leading to a significant reduction 
in the peak sodium current. This effect is specific to Nav1.7 as overexpressing the Nav1.7 
NAT in a stable Nav1.6 cell line had no effect on peak sodium current.  Whether the SCN9A 
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natural antisense transcript negatively regulates SCN9A by RNAi or RNA masking is not 
known. However, this result gives scope to further investigating the effect of overexpressing 
the NAT in a cell which endogenously expresses Nav1.7. Furthermore, what is particularly 
exciting is the possibility that downregulation of the NAT (and hence upregulation of SCN9A) 
might underlie different pain states. To investigate this, we plan to assess the mRNA level of 
the sense and antisense gene in inflammatory and neuropathic mouse pain models using 
quantitative RT-PCR. Furthermore, the Nav1.7 protein level will also be monitored by 
western blotting in these pain models. Another interesting experiment planned is to use 
RNA in situ hybridization to study the localization of the NATs within a primary DRG neuron 
so that the effect of the NAT on local protein synthesis can be explored. 
As mentioned earlier (results, 6.1 Bioinformatics) the human and mouse antisense 
transcript share one highly conserved exon. It will therefore be interesting to see if 
transfection the of the human Nav1.7 cell line with mouse EXPM1 antisense transcript also 
has an effect on electrophysical properties of the human Nav1.7 voltage gated sodium 
channel. Overexpression of human antisense gene in a stable Nav1.7 cell line leads to a 
reduction of peak current. In case the conserved exon plays a central part in antisense 
mediated regulation in both human and mouse it is expected that we will observe the same 
reduction in sodium peak current as seen with the human antisense transcript. If so, his 
would point toward a conserved regulatory mechanism which could then be explored 
further.  
Nav1.7 is essential in nociception and not involved in any other major cellular pathways 
other than pain and the olfactory pathway. Therefore the Nav1.7 voltage gated sodium 
channel is an attractive target for a new class of analgesic drugs. Assuming that the SCN9A 
natural antisense transcript regulates endogenous SCN9A, it could be possible to interfere 
and control this regulation and thereby control the level of functional Nav1.7 sodium 
channels in DRG neurons in the clinic. Similarly, it has been postulated that a natural 
antisense transcript to the Huntington’s disease gene may have clinical applications (Ref is 
Chung et al 2011). So by fine tuning the level of functional Nav1.7 via antisense transcript 
expression it could be possible to restore normal pain thresholds even in patients suffering 
from inherited forms of Nav1.7 dysregulation. 
 
 
  
56 | P a g e  
 
References  
 
1. Lapidot M, Pilpel Y. Genome-wide natural antisense transcription: coupling its 
regulation to its different regulatory mechanisms. EMBO Rep. 2006 
Dec; 7(12):1216-22. Review. PubMed PMID: 17139297; PubMed Central PMCID: 
PMC1794690. 
2. Werner A, Carlile M, Swan D. What do natural antisense transcripts regulate? 
RNA Biol. 2009 Jan-Mar; 6(1):43-8. Epub 2009 Jan 2. Review. PubMed PMID: 
19098462. 
3. Natural antisense transcript regulates gene expression in an epigenetic manner, Su 
WY, Xiong H, Fang JY.Biochem Biophys Res Commun. 2010 May 28; 396(2):177-81. 
Epub 2010 May 8. Review. PMID: 20438699 
4. Lavorgna G, Dahary D, Lehner B, Sorek R, Sanderson CM, Casari G. In search of  
Antisense. Trends Biochem Sci. 2004 Feb; 29(2):88-94. Review. PubMed PMID: 
15102435. 
5. Beiter T, Reich E, Williams RW, Simon P. Antisense transcription: a critical look in 
both directions. Cell Mol Life Sci. 2009 Jan; 66(1):94-112. Review. PubMed 
PMID: 18791843 
6. Werner A, Sayer JA. Naturally occurring antisense RNA: function and mechanisms 
of action. Curr Opin Nephrol Hypertens. 2009 Jul; 18(4):343-9. Review. PubMed 
PMID: 19491676.  
7. Werner A, Berdal A. Natural antisense transcripts: sound or silence? Physiol 
Genomics. 2005 Oct 17; 23(2):125-31. Review. PubMed PMID: 16230481. 
8.  , Herbert A. The four Rs of RNA-directed evolution. Nat Genet. 2004 Jan; 36(1):19-
25. Review. PubMed PMID: 14702037. 
9.  Lampert A, O'Reilly AO, Reeh P, Leffler A. Sodium channelopathies and pain. 
Pflugers Arch. 2010 Jul; 460(2):249-63. Epub 2010 Jan 26. Review. PubMed PMID: 
20101409. 
10.  Larry Squire, Floyd E. Bloom, Nicholas C. Spitzer, Larry R. Squire, Darwin Berg, Floyd 
E. Bloom, Sascha du Lac, Anirvan Ghosh  &  Nicholas C. Spitzer Fundamental 
Neuroscience , 3rd edition , chapter  
  
57 | P a g e  
 
11. Waxman et al Neuroscience: channelopathies have many faces Nature 2011 Apr 14; 
472(7342):173-4. 
12. Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. From genes to pain: Na v 1.7 and 
human pain disorders. Trends Neurosci. 2007 Nov; 30(11):555-63. Epub 2007 Oct 22. 
Review. PubMed PMID: 17950472. 
13. Cummins TR, Sheets PL, Waxman SG. The roles of sodium channels in nociception: 
Implications for mechanisms of pain. Pain. 2007 Oct; 131(3):243-57. Epub 2007 Sep 
4. Review. PubMed PMID: 17766042; PubMed Central PMCID: PMC2055547. 
14. Drenth JP, Waxman SG. Mutations in sodium-channel gene SCN9A cause a spectrum 
of human genetic pain disorders. J Clin Invest. 2007 Dec; 117(12):3603-9. Review. 
PubMed PMID: 18060017; PubMed Central PMCID: PMC2096434. 
15. Pain channelopathies Roman Cregg, Aliakmal Momin, Francois Rugiero, John N 
Wood, Jing Zhao J Physiol. 2010 June 1; 588(Pt 11): 1897–1904.   Published online 
2010 February 8.  doi: 10.1113/jphysiol.2010.187807 PMCID: PMC2901978 
16. Cummins TR, Dib-Hajj SD, Waxman SG. Electrophysiological properties of mutant 
Nav1.7 sodium channels in a painful inherited neuropathy. J Neurosci. 2004 Sep22; 
24(38):8232-6. PubMed PMID: 15385606. 
17. Waxman et al Neuroscience: channelopathies have many faces Nature 2011 Apr 14; 
472(7342):173-4. 
18. Kandel James H. Schwartz Thomas M. Jessell , Fundamentals of Neural science ,4th 
edition , chapter 24 , The perception of pain pt 404-420  
19. Isom, L. L. 2002. Beta subunits: players in neuronal hyperexcitability? Novartis 
Found. Symp. 241, 124–138; discussion 138–143, 226–232. 
20. Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, Karbani G, Jafri H, 
Mannan J,Raashid Y, Al-Gazali L, Hamamy H, Valente EM, Gorman S, Williams R, 
McHale DP, Wood JN,Gribble FM, Woods CG. An SCN9A channelopathy causes 
congenital inability to experience pain. Nature 2006; 444:894–898. [PubMed: 
17167479] 
21. The sense a comprehensive Reference , Volume 5 , Pain , section 5.07 sodium 
channels , John N Wood p.89-95 , Elsevier 2008 
22. The Immunoglobulin Superfamily—Domains for Cell Surface Recognition 
Annual Review of Immunology Vol. 6: 381-405 (Volume publication date April 1988) 
  
58 | P a g e  
 
DOI: 10.1146/annurev.iy.06.040188.002121 
23. Catterall W.A. From ionic currents to molecular mechanisms: The structure and 
function of voltage-gated sodium channels (2000) Neuron, 26 (1), pp. 13-25. 
24.  Planells-Cases R, et al. 2000. Neuronal death and perinatal lethality in voltage-gated 
sodium channel alpha (II)-deficient mice. Biophys J 78:2878 –2891. 
25. Wood, J. N., Boorman, J. P., Okuse, K. and Baker, M. D. (2004), Voltage-gated sodium 
channels and pain pathways. Journal of Neurobiology, 61: 55–71. doi: 
10.1002/neu.20094 
26. Lehmann-Horn F, Jurkat-Rott K, Rudel R. 2002. Periodic paralysis: understanding 
channelopathies. Curr Neurol Neurosci Rep 2:61– 69 
27. Loss of function mutation in sodium channel Nav1.7 causes anomia ,Weiss J, Pyrski 
M, Jacobi E, Bufe B, Willnecker V, Schick B, Zizzari P, Gossage SJ, Greer CA, Leinders-
Zufall T, Woods CG, Wood JN, Zufall F. Nature. 2011 Apr 14; 472(7342):186-90. Epub 
2011 Mar PMID:21441906 
28. Pain as a Channelopathy Raouf R, Quick K, Wood JN. J Clin Invest. 2010 Nov 1; 
120(11):3745-52. doi: 10.1172/JCI43158. Epub 2010 Nov 1. Review. 
29. Dib-Hajj SD, Binshtok AM, Cummins TR, Jarvis MF, Samad T, Zimmermann K. 
Voltage-gated sodium channels in pain states: role in pathophysiology and targets 
for treatment. Brain Res Rev. 2009 Apr; 60(1):65-83. Epub 2008 Dec 25. Review. 
PubMed PMID: 19150627. 
30. Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. Sodium channels in normal and 
pathological pain. Annu Rev Neurosci. 2010; 33:325-47. Review. PubMed PMID: 
20367448 
31. Nassar MA, Stirling LC, Forlani G, Baker MD, Matthews EA, et al. 2004. Nociceptor-
specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and 
inflammatory pain. Proc. Natl. Acad. Sci. USA 101:12706–11 
32. Nassar MA, Levato A, Stirling C,Wood JN. 2005. Neuropathic pain develops normally 
in mice lacking both Nav1.7 and Nav1.8. Mol. Pain 1:24 
33. Nassar MA, Baker MD, Levato A, Ingram R, Mallucci G, et al. 2006. Nerve injury 
induces robust allodynia and ectopic discharges in Nav1.3 null mutant mice. Mol. 
Pain 2:33 
34. Fischer TZ, Waxman SG. Familial pain syndromes from mutations of the Nav1.7 
  
59 | P a g e  
 
sodium channel. Ann N Y Acad Sci. 2010 Jan; 1184:196-207. Review. PubMed PMID: 
20146699 
35. Marban, E., Yamagishi, T. & Tomaselli, G.F. Structure and function of voltage-gated 
sodium channels. J Physiol 508 (Pt 3), 647-57 (1998). 
36. Klugbauer, N., Lacinova, L., Flockerzi, V. & Hofmann, F. Structure and functional 
expression of a new member of the tetrodotoxin-sensitive voltage-activated sodium 
channel family from human neuroendocrine cells. Embo J 14, 1084-90 (1995). 
37. Herzog, R.I., Cummins, T.R., Ghassemi, F., Dib-Hajj, S.D. & Waxman, S.G. Distinct 
repriming and closed-state inactivation kinetics of Nav1.6 and Nav1.7 sodium 
channels in mouse spinal sensory neurons. J Physiol 551, 741-50 (2003). 
38. Wulff BE, Sakurai M, Nishikura K. Elucidating the inosinome: global approaches 
to adenosine-to-inosine RNA editing. Nat Rev Genet. 2011 Feb; 12(2):81-5. Epub 
2010 Dec 21. PubMed PMID: 21173775; PubMed Central PMCID: PMC3075016. 
39. Zinshteyn B, Nishikura K. Adenosine-to-inosine RNA editing. Wiley Interdiscip  
Rev Syst Biol Med. 2009 Sep-Oct;1(2):202-9. Review. PubMed PMID: 20835992; 
PubMedCentral PMCID: PMC2946787 
40. Nishikura K. Editor meets silencer: crosstalk between RNA editing and RNA 
Interference. Nat Rev Mol Cell Biol. 2006 Dec;7(12):919-31. Review. PubMed PMID:  
17139332; PubMed Central PMCID: PMC2953463. 
41. Athanasiadis A, Rich A, Maas S. Widespread A-to-I RNA editing of 
Alu-containing mRNAs in the human transcriptome. PLoS Biol. 2004 Dec;2(12):e391.  
Epub 2004 Nov 9. PubMed PMID: 15534692; PubMed Central PMCID: PMC526178. 
42. Maas S, Kawahara Y, Tamburro KM, Nishikura K. A-to-I RNA editing and human 
disease. RNA Biol. 2006 Jan-Mar; 3(1):1-9. Epub 2006 Jan 12. Review. PubMed PMID:  
17114938; PubMed Central PMCID: PMC2947206. 
43. Abrahamsen B, Zhao J, Asante CO, Cendan CM, Marsh S, Martinez-Barbera JP,Nassar 
MA, Dickenson AH, Wood JN. The cell and molecular basis of mechanical,cold, and 
inflammatory pain. Science. 2008 Aug 1; 321(5889):702-5. PubMed PMID: 18669863. 
44. Regulatory roles of natural antisense transcripts .Mohammad Ali Faghihi, Claes 
Wahlestedt Nat Rev Mol Cell Biol.  Author manuscript; available in PMC 2010 April 7. 
Published in final edited form as:   Nat Rev Mol Cell Biol.  2009 September; 10 (9): 
  
60 | P a g e  
 
637–643.  Published online 2009 July 29.  doi: 10.1038/nrm2738 PMCID: 
PMC2850559 
45. Faghihi MA, Zhang M, Huang J, Modarresi F, Van der Brug MP, Nalls MA, Cookson 
MR, St-Laurent G 3rd, Wahlestedt C. Evidence for natural antisense transcript-
mediated inhibition of microRNA function. Genome Biol. 2010; 11(5):R56.Epub 2010 
May 27. PubMed PMID: 20507594; PubMed Central PMCID: PMC2898074. 
46. Uchida T, Rossignol F, Matthay MA, Mounier R, Couette S, Clottes E, Clerici 
C.Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1alpha 
and HIF-2alpha expression in lung epithelial cells: implication of natural 
Antisense HIF-1alpha. J Biol Chem. 2004 Apr 9; 279(15):14871-8. Epub 2004 Jan 26. 
PubMed PMID: 14744852. 
47. Osato N, Suzuki Y, Ikeo K, Gojobori T. Transcriptional interferences in cis-natural 
antisense transcripts of humans and mice. Genetics. 2007Jun; 176(2):1299-306. Epub 
2007 Apr 3. PubMed PMID: 17409075; PubMed Central PMCID: PMC1894591. 
48. Farnebo M. Wrap53, a novel regulator of p53. Cell Cycle. 2009 Aug; 8(15):2343-6. 
Epub 2009 Aug 8. PubMed PMID: 19571673. 
49. Payer B, Lee JT. X chromosome dosage compensation: how mammals keep the 
balance. Annu Rev Genet. 2008; 42:733-72. Review. PubMed PMID: 18729722. 
50. Lee JT, Davidow LS, Warshawsky D. Tsix, a gene antisense to Xist at the X-inactivation 
centre. Nat Genet. 1999 Apr; 21(4):400-4. PubMed PMID: 10192391. 
51. Zhou H, Hu H, Lai M. Non-coding RNAs and their epigenetic regulatory mechanisms. 
Biol Cell. 2010 Dec; 102(12):645-55. Review. PubMed PMID: 21077844 
52. Chen, Z., Place, R.F., Jia, Z.J., Pookot, D., Dahiya, R. and Li, L.C. (2008) Antitumor 
effect of dsRNA-induced p21 (WAF1/CIP1) gene activation in human bladder cancer 
cells. Mol. Cancer Ther. 7, 698-703 
53. Herbert A. The four Rs of RNA-directed evolution. Nat Genet. 2004Jan; 36(1):19-25. 
Review. PubMed PMID: 14702037. 
54. Nav1.9 Channel Contributes to Mechanical and Heat Pain Hypersensitivity Induced 
by Subacute and Chronic Inflammation Stéphane Lolignier, Muriel Amsalem, François 
Maingret, Françoise Padilla, Mélanie Gabriac, Eric Chapuy, Alain Eschalier, Patrick 
Delmas, Jérôme Busserolle PLoS One. 2011; 6(8): e23083.   Published online 2011 
August 12.  doi: 10.1371/journal.pone.0023083 PMCID: PMC3155549 
  
61 | P a g e  
 
55. Wutz A, Gribnau J. X inactivation Xplained. Curr Opin Genet Dev. 2007 Oct; 
17(5):387-93. Epub 2007 Sep 14. Review. PubMed PMID: 17869504. 
56. M Pearce*, C Jurinke, and P Oeth. Reference gene selection for gene expression 
studies. Sequenome  
57. Raymond CK, Castle J, Garrett-Engele P, Armour CD, Kan Z, Tsinoremas N, 
Johnson JM. Expression of alternatively spliced sodium channel alpha-subunit genes. 
Unique splicing patterns are observed in dorsal root ganglia. J Biol Chem. 
2004 Oct 29; 279(44):46234-41. Epub 2004 Aug 9. PubMed PMID: 15302875. 
58. Meguro K, Iida H, Takano H, Morita T, Sata M, Nagai R, Nakajima T. Function and role 
of voltage-gated sodium channel NaV1.7 expressed in aortic smooth muscle 
cells. Am J Physiol Heart Circ Physiol. 2009 Jan; 296(1):H211-9. Epub 2008 Oct 
PubMed PMID: 18978189. 
59. Platoshyn O, Remillard CV, Fantozzi I, Sison T, Yuan JX. Identification of functional 
voltage-gated Na(+) channels in cultured human pulmonary artery smooth 
muscle cells. Pflugers Arch. 2005 Nov; 451(2):380-7. Epub 2005 Jul 29. PubMed 
PMID: 16052353; PubMed Central PMCID: PMC1351366. 
60. Dar R., Ariely D., Frenk H.The effect of past-injury on pain threshold and 
tolerance(1995) Pain, 60 (2), pp. 189-193. 
61. Dichgans M, Freilinger T, Eckstein G, Babini E, Lorenz-Depiereux B, Biskup S, Ferrari 
MD, Herzog J, van den Maagdenberg AM, Pusch M, Strom TM. Mutation in the 
neuronal voltage-gated sodium channel SCN1A in familial hemiplegic 
migraine.Lancet. 2005 Jul 30-Aug 5; 366(9483):371-7. PubMed PMID: 16054936. 
62. Fertleman CR, Baker MD, Parker KA, Moffatt S, Elmslie FV, Abrahamsen B, Ostman J, 
Klugbauer N, Wood JN, Gardiner RM, Rees M. SCN9A mutations in paroxysma 
lextreme pain disorder: allelic variants underlie distinct channel defects and 
phenotypes. Neuron. 2006 Dec 7; 52(5):767-74. PubMed PMID: 17145499. 
63. Priest BT, Murphy BA, Lindia JA, Diaz C, Abbadie C, Ritter AM, Liberator P,Iyer LM, 
Kash SF, Kohler MG, Kaczorowski GJ, MacIntyre DE, Martin WJ.Contribution of the 
tetrodotoxin-resistant voltage-gated sodium channel NaV1.9 tosensory transmission 
and nociceptive behavior. Proc Natl Acad Sci U S A. 2005 Jun28; 102(26):9382-7. 
Epub 2005 Jun 17. PubMed PMID: 15964986; PubMed Central PMCID: PMC1166597. 
  
62 | P a g e  
 
64. Akopian AN, Souslova V, England S, Okuse K, Ogata N, Ure J, Smith A, Kerr BJ, 
McMahon SB, Boyce S, Hill R, Stanfa LC, Dickenson AH, Wood JN. The tetrodotoxin-
resistant sodium channel SNS has a specialized function in pain pathways. Nat 
Neurosci. 1999 Jun; 2(6):541-8. PubMed PMID: 10448219. 
65. Wilde AA, Brugada R. Phenotypical manifestations of mutations in the 
genesencoding subunits of the cardiac sodium channel. Circ Res. 2011 Apr 
1;108(7):884-97. Review. PubMed PMID: 21454796. 
66. Levin SI, Khaliq ZM, Aman TK, Grieco TM, Kearney JA, Raman IM, Meisler 
MH.Impaired motor function in mice with cell-specific knockout of sodium channel 
Scn8a (NaV1.6) in cerebellar purkinje neurons and granule cells. J Neurophysiol.  
2006 Aug;96(2):785-93. Epub 2006 May 10. PubMed PMID: 16687615 
 
 
Weblinks and Bioinformatic databases: Overview  
 
• International Association for the Study of Pain: IASP Taxomy 
  http://www.iasp-pain.org  
• Fantom mouse consortium , full  mouse  antisense clone description  
             http://www.dnaform.jp/products/fantom/pd f/FANTOM-PX-PY-PZ.pdf  
• RestrictionMapper http://www.restrictionmapper.org/  
• Double Digest Finder http://www.neb.com/nebecomm/DoubleDigestCalculator.asp  
• Genome UCSC http://genome.ucsc.edu  
• NCBI Blast http://blast.ncbi.nlm.nih.gov/Blast.cgi  
• For full information on pEGFP vector with MCS 
http://www.pkclab.org/PKC/vector/pEGFPN1.pdf 
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SUPPLEMENTAL DATA  Diplomarbeit - Jennifer König  
 
SUPPLEMENTAL DATA 1 -SCN9A protein structure 
 
Primary amino acid sequence (5N+11RS) 
 
               10        20        30        40        50        60 
./wwwt MAMLPPPGPQSFVHFTKQSLALIEQRIAERKSKEPKEEKKDDDEEAPKPSSDLEAGKQLP 
 
               70        80        90       100       110       120 
./wwwt FIYGDIPPGMVSEPLEDLDPYYADKKTFIVLNKGKTIFRFNATPALYMLSPFSPLRRISI 
 
              130       140       150       160       170       180 
./wwwt KILVHSLFSMLIMCTILTNCIFMTMNNPPDWTKNVEYTFTGIYTFESLVKILARGFCVGE 
 
              190       200       210       220       230       240 
./wwwt FTFLRDPWNWLDFVVIVFAYLTEFVNLGNVSALRTFRVLRALKTISVIPGLKTIVGALIQ 
 
              250       260       270       280       290       300 
./wwwt SVKKLSDVMILTVFCLSVFALIGLQLFMGNLKHKCFRNSLENNETLESIMNTLESEEDFR 
 
              310       320       330       340       350       360 
./wwwt KYFYYLEGSKDALLCGFSTDSGQCPEGYTCVKIGRNPDYGYTSFDTFSWAFLALFRLMTQ 
 
              370       380       390       400       410       420 
./wwwt DYWENLYQQTLRAAGKTYMIFFVVVIFLGSFYLINLILAVVAMAYEEQNQANIEEAKQKE 
 
              430       440       450       460       470       480 
./wwwt LEFQQMLDRLKKEQEEAEAIAAAAAEYTSIRRSRIMGLSESSSETSKLSSKSAKERRNRR 
 
              490       500       510       520       530       540 
./wwwt KKKNQKKLSSGEEKGDAEKLSKSESEDSIRRKSFHLGVEGHRRAHEKRLSTPNQSPLSIR 
 
              550       560       570       580       590       600 
./wwwt GSLFSARRSSRTSLFSFKGRGRDIGSETEFADDEHSIFGDNESRRGSLFVPHRPQERRSS 
 
              610       620       630       640       650       660 
./wwwt NISQASRSPPMLPVNGKMHSAVDCNGVVSLVDGRSALMLPNGQLLPE//GTTNQIHKKRRCS 
 
              670       680       690       700       710       720 
./wwwt SYLLSEDMLNDPNLRQRAMSRASILTNTVEELEESRQKCPPWWYRFAHKFLIWNCSPYWI 
 
              730       740       750       760       770       780 
./wwwt KFKKCIYFIVMDPFVDLAITICIVLNTLFMAMEHHPMTEEFKNVLAIGNLVFTGIFAAEM  
 
              790       800       810       820       830       840 
./wwwt VLKLIAMDPYEYFQVGWNIFDSLIVTLSLVELFLADVEGLSVLRSFRLLRVFKLAKSWPT 
 
              850       860       870       880       890       900 
./wwwt LNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKECVCKINDDCTLPRWHMN 
 
              910       920       930       940       950       960 
./wwwt DFFHSFLIVFRVLCGEWIETMWDCMEVAGQAMCLIVYMMVMVIGNLVVLNLFLALLLSSF 
 
              970       980       990      1000      1010      1020 
./wwwt SSDNLTAIEEDPDANNLQIAVTRIKKGINYVKQTLREFILKAFSKKPKISREIRQAEDLN 
 
             1030      1040      1050      1060      1070      1080 
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./wwwt TKKENYISNHTLAEMSKGHNFLKEKDKISGFGSSVDKHLMEDSDGQSFIHNPSLTVTVPI 
 
             1090      1100      1110      1120      1130      1140 
./wwwt APGESDLENMNAEELSSDSDSEYSKVRLNRSSSSECSTVDNPLPGEGEEAEAEPMNSDEP 
 
             1150      1160      1170      1180      1190      1200 
./wwwt EACFTDGCVRRFSCCQVNIESGKGKIWWNIRKTCYKIVEHSWFESFIVLMILLSSGALAF 
 
             1210      1220      1230      1240      1250      1260 
./wwwt EDIYIERKKTIKIILEYADKIFTYIFILEMLLKWIAYGYKTYFTNAWCWLDFLIVDVSLV 
 
             1270      1280      1290      1300      1310      1320 
./wwwt TLVANTLGYSDLGPIKSLRTLRALRPLRALSRFEGMRVVVNALIGAIPSIMNVLLVCLIF 
 
             1330      1340      1350      1360      1370      1380 
./wwwt WLIFSIMGVNLFAGKFYECINTTDGSRFPASQVPNRSECFALMNVSQNVRWKNLKVNFDN 
 
             1390      1400      1410      1420      1430      1440 
./wwwt VGLGYLSLLQVATFKGWTIIMYAAVDSVNVDKQPKYEYSLYMYIYFVVFIIFGSFFTLNL 
 
             1450      1460      1470      1480      1490      1500 
./wwwt FIGVIIDNFNQQKKKLGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPGNKIQGCIFDL 
 
             1510      1520      1530      1540      1550      1560 
./wwwt VTNQAFDISIMVLICLNMVTMMVEKEGQSQHMTEVLYWINVVFIILFTGECVLKLISLRH  
 
             1570      1580      1590      1600      1610      1620 
./wwwt YYFTVGWNIFDFVVVIISIVGMFLADLIETYFVSPTLFRVIRLARIGRILRLVKGAKGIR 
 
             1630      1640      1650      1660      1670      1680 
./wwwt TLLFALMMSLPALFNIGLLLFLVMFIYAIFGMSNFAYVKKEDGINDMFNFETFGNSMICL 
 
             1690      1700      1710      1720      1730      1740 
./wwwt FQITTSAGWDGLLAPILNSKPPDCDPKKVHPGSSVEGDCGNPSVGIFYFVSYIIISFLVV 
 
             1750      1760      1770      1780      1790      1800 
./wwwt VNMYIAVILENFSVATEESTEPLSEDDFEMFYEVWEKFDPDATQFIEFSKLSDFAAALDP 
 
             1810      1820      1830      1840      1850      1860 
./wwwt PLLIAKPNKVQLIAMDLPMVSGDRIHCLDILFAFTKRVLGESGEMDSLRSQMEERFMSAN 
 
             1870      1880      1890      1900      1910      1920 
./wwwt PSKVSYEPITTTLKRKQEDVSATVIQRAYRRYRLRQNVKNISSIYIKDGDRDDDLLNKKD 
 
             1930      1940      1950      1960      1970        
./wwwt MAFDNVNENSSPEKTDATSSTTSPPSYDSVTKPDKEKYEQDRTEKEDKGKDSKESKK 
 
 
Ion selectivity pore (PAPER) 1 
A re-entrant loop between helices S5 and S6 is embedded into the transmembrane region of 
the channel to form the narrow, ion-selective filter at the extracellular end of the pore. 
 
In ion trans I:  356-365 
In ion trans II:  911-920 
In ion trans III: 1390-1399 
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In ion trans IV: 1682-1691 
 
 
Transmembrane regions (Klugbauer) 
Sodium Ion transport associated domain (SMART) 
969-1191 
 
Coiled coil region 
402-449 
 
IQ 
1877-1899 
 
Mutations 
pedigree 44324 S459X 
 
pedigree 22310 W897X 
 
pedigree 21706 I767X 
 
SNPs 
rs12478318  G/T  ML 
rs4369876  A/C  VL 
rs6746030  A/G  RW 
rs3750904  C/T  DG 
 
Splice variants 
Alternative coding exon 5: 
YLTEFVNLGNVSALRTFRVLRALKTISVIP 
YVTEFVDLGNVSALRTFRVLRALKTISVIP 
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For SCN8A it is said that this sequence encodes parts of transmembrane segments S3 and S4 
within domain I 2,3. 
 
Extension of coding exon 11 at //: 
VIIDKATSDDS 
 
For SCN8A it is said that this encodes a portion of the cytoplasmic loop between domains I 
and II 4. 
 
IFM motif 
In italics is the IFM motif. The sequence contains the IFM motif and the charged residues in 
the domain III-IV linker identified to be critical for the fast inactivation kinetics of the rat 
brain II channel 5. 
 
Tetrodotoxin amino acid 
Highlighted in black is Y362 which can be mutated to Serine to make the channel 
tetrodotoxin-resistant 6. 
 
1. Marban, E., Yamagishi, T. & Tomaselli, G.F. Structure and function of voltage-gated 
sodium channels. J Physiol 508 ( Pt 3), 647-57 (1998). 
2. Plummer, N.W., McBurney, M.W. & Meisler, M.H. Alternative splicing of the 
sodium channel SCN8A predicts a truncated two-domain protein in fetal brain and 
non-neuronal cells. J Biol Chem 272, 24008-15 (1997). 
3. Plummer, N.W. et al. Exon organization, coding sequence, physical mapping, and 
polymorphic intragenic markers for the human neuronal sodium channel gene 
SCN8A. Genomics 54, 287-96 (1998). 
4. Dietrich, P.S. et al. Functional analysis of a voltage-gated sodium channel and its 
splice variant from rat dorsal root ganglia. J Neurochem 70, 2262-72 (1998). 
5. Klugbauer, N., Lacinova, L., Flockerzi, V. & Hofmann, F. Structure and functional 
expression of a new member of the tetrodotoxin-sensitive voltage-activated sodium 
channel family from human neuroendocrine cells. Embo J 14, 1084-90 (1995). 
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6. Herzog, R.I., Cummins, T.R., Ghassemi, F., Dib-Hajj, S.D. & Waxman, S.G. Distinct 
repriming and closed-state inactivation kinetics of Nav1.6 and Nav1.7 sodium 
channels in mouse spinal sensory neurons. J Physiol 551, 741-50 (2003). 
 
 
Supplemental data 2 – Full length antisense, cDNA sequence Mouse  
 
 
Sequence: AK 138532 
 
  1 gagcaagagt aagaagtatt ggcagcagca agcaggcggg caggctgaga tcttgcatgg 
 61 aaatcatgaa ccaggtcttg cttttcgttt ttgaaacgtt ttggaaggag agttatgaat 
121 agcccagaaa taggtctcat tttgtgggta ggaagaatga ccagaagcat gaaagctaaa 
181 tctcctggca agtgcagggg acctctcttg gagtgtgcag taaacccgag gggacgactt 
241 ctcctgctgt caactcctga accatcacat ctggagtgaa ggaaggggct ggtgaagcct 
301 tgtaataaat gcaaaggatg ctgctgagag ctttggtctg cctttaactc attgtggcaa 
361 agttggacat cccaaagatg gcgtagatga acatgacgag gaaaagcagg aggccgatgt 
421 tgaacagcgc aggaagggac atcatcagag caaagagcag cgtgcggatc cccttggcgc 
481 ctttgatcag gcgtaggatt cgtccaatcc tggccaggcg aatgactcgg aacaggatgc 
541 tactcccagt cttcactgag aaactgctct agccagtgaa cgacagtgaa tgaagaaatg 
601 cctggctgct cgagacaccg agagtgacag ctgcgtgctc agctcaggag gacgttcata 
661 tccttcttca aggctctagg aacaaagcgt ggtgatgaca ggaagacagt aagagcccag 
721 gacataggga tgggagctat gaagctctgt gctgtaccaa ggacacaatc aatgtaatcg 
781 cggcaccata acagaggtca gcagtgggtt cgtgcaatac tgagcgggtc agcattcatt 
841 cattcatata cagagagggc ccatgcagcc acatcttctc tgctgaatta tgagctaccg 
901 atggattgtg ggagaaacaa acattctctt cagccttggg cccacttctg agttcactag 
961 gttaaacttc ttcgatgttg gcctggttct gttcctcgta cgccatggct accacagcca 
1021 ggatcaagtt tatcaggtaa aaggatccca gaaatatcac cacgacaaag aaaatcatgt 
1081 aggttttgcc agcagcacgc agtgtctatg gggagcaaaa aagagacatg attattttag 
1141 taatacaaaa atttcactaa ggtttttatt gcagctagta tataatgaat gtgcaaacca 
1201 gatatttttg tataattttg ttgtagaaag ataaataaag ataatatctt tgaggaaaat 
1261 cagtattaaa caaacttttt aatataaaag atacagcatt gttatatgta cattaaggct 
1321 tgattcttca ttaaaatgaa atataatggc 
  
68 | P a g e  
 
 
Human full length antisense , cDNA sequence  
Sequence = BC051759 
 
gtcttagtcc tctgaatatt ttttctttgt tcagaacctg agaaagatga atgaaattta 
       61 gtgtttccca tccccgagag acacccagca tccacaactt cacactctga tgccattgtg 
      121 tatttatgca agaaatacca taactaagat gaggtctcgc tatgttgcct aggctagtct 
      181 tgaactcctg gcctcaagtg atccttctgc ctcagcatcg ggagtcactg ggattaaagg 
      241 catgagccac catgctcagg aacttgacat catcagacag taaatcaaga ggtactgaca 
      301 actgagactg agtgatggtc cctgcctagg atttggaatc tttgcatgaa atagggactc 
      361 tagccaccag cgacaaagaa gtcagggaga ctgcggtctc taggaagcac ttccaggaaa 
      421 caggaattca ggcaaagttg gacattccaa agatggcgta gatgaacatg accaggaaga 
      481 gcaggaggcc gatgttaaac aacgcaggaa gggacatcat caaagcaaag agcagcgtgc 
      541 ggatcccctt tgctcctttg actagacgta ggattcggcc aatcctggca agacggatca 
      601 ctcggaacag ggtaacagag atctctggag gtgaaacatt gctctgaact ggcattgatt 
      661 ctagcccagc tcttgtagac caattaccaa cttgtccatc tccctccagt gcctggaact 
      721 ggacctggca cacaggcctc tggctcatcg gaattcatag gttcagcctc tgcttcttct 
      781 ccttctccag gcaaagggtt atcaactgtg ctgcactctg aggagcttga ccggtttaat 
      841 ctctagaaag gaattcacca ccccaccagc acgcggaaca caatcaggaa ggagtggaag 
      901 aagtcgttca tgtgccaccg tgggagcgta cagtcatcat tgatcttgca gacacattct 
      961 ttgtagctct taccaaagag ctgcatgccg accacagcaa aaatgaagac gatgatggcc 
     1021 aacactaagc ctttagacta aaaagaaaac aaatattaca taccctgaat ctgtgctgaa 
     1081 accacaaagg agagcatctt tggatccttc caagtaataa aaatattctg ttgaagaaga 
     1141 atttgaacag ttataacatc acagacttta atctgtgatt gtgataaagg aggtcaaatt 
     1201 aaaaaatctg attattggga gacttttgga gtaatcatgg aagaaagact atgaaatcag 
     1261 atattcttgg atttgaatgt tgcttctatc ccttcttaac ttaaatccat gggcattcat 
     1321 tatcatcagt gcctaacctg gcagaaccac agtctacaca taatctggca tctgtctttt 
     1381 ccatgctggc taccaaatgg ctgaatgttg gtggagaaac tctcacaacc aagtgaatgg 
     1441 ttatatttta atttcgctct tgttgcccag tctggagtgc aatggcacga tctcggctca 
     1501 ccgcaacctc tgcctcccga gttcaagcga ttctcctgcc tcagcctcct gagtagctgg 
     1561 aattacaggc acccaccacc atgcccggct aattttttgt atttttagta gagacggggt 
     1621 ttcttttttt ttcttctttt tttgtattat tttttagcaa aaaaaaaaaa aaaatacatg 
     1681 aagcaattcc agaaagcgat gaattaaatt aaatttgatt aaaggctgtc tgtgtacata 
     1741 gagaattgca atctaacttc atatgtaaac aaattgcatt ctaatctatt agtatattct 
     1801 tgtaacaagt agctgtctca gccaatcaca gcagctgagc ttcagccaac cacagcctgc 
     1861 tgatttatca gacaatgtcc acataaggca aatgtcaagc tataagcaat caagctgttt 
     1921 ttgtgcgtca ctcccttttt ctgtctataa atactcctgc tcatgttgct gagttgagct 
     1981 ctccgaactt ctcttggttc tgagtgctgc ctaaatcatt attattatta tcttatttca 
     2041 gcaataaata ctatttcatt gctgaaataa gctgctaaat ttaatttgtt gaaaattttt 
     2101 cttttaacaa aggttaagaa aaccattcac agtataaact cagaaatagg agcaagactc 
     2161 agaataaaag gacagatccc agtgagaaaa cttaagttta aataagtgtg gtaaaataat 
     2221 ctacaatatt aaatgtaagt tactcatcag atatattaat tttacagcat ataaattaag 
     2281 aaataaaatt ctccatcaat tgg 
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Appendix – Diplomarbeit Jennifer König  
 
  
AP1.1 1 kb DNA Ladder, Invitrogen  
http://products.invitrogen.com/ivgn/product/10787018  
AP1.2 1 100kp DNA Ladder, Invitrogen  
` http://products.invitrogen.com/ivgn/product/15628019  
AP1.31    OneShot© Top10 chemically competent cells (Invitrogen C4040-10) 
 http://products.invitrogen.com/ivgn/product/C404010  
AP1.4  XL10-Gold ultracompetent Cells (Stratagene C- 200314).  
http://www.freewebs.com/labjuan2/XL10%20competent%20cells%20STRATAGENE.
pdf  
AP1.5 Miniprep (Qiagen Spin Miniprep kit)- Handbook 
 http://www.qiagen.com/literature/handbooks/literature.aspx?id=1000248  
AP1.6 Maxiprep protocol see appendix Qiagen High speed Maxiprep kit 
http://www.qiagen.com/products/plasmid/qiagenplasmidpurificationsystem/hispee
dplasmidmidikit.aspx?rp=1000096&rpg=0  
AP1.7 Gel purification, Qiagen Gel purification kit 
http://www.qiagen.com/products/dnacleanup/gelpcrsicleanupsystems/qiaquickgele
xtra  ctionkit.aspx?rp=1000252&rpg=0  
AP1.8 PCR Purification 
http://www.qiagen.com/products/dnacleanup/gelpcrsicleanupsystems/qiaquickpcrp
urificationkit.aspx?rp=1000254&rpg=0  
AP1.9 SuperScript RT (Invitrogen)  
http://www.invitrogen.com/site/us/en/home/Products-and-
Services/Applications/Nucleic-Acid-Amplification-and-Expression-Profiling/RT-
PCR/superscript-iii-first-strand-synthesis-system-for-rt-pcr.html  
AP1.10 Phusion high fidelity PCR kit, Finnzymes F-553S/L 
 http://www.finnzymes.com/pcr/phusion_high_fidelity_pcr_kit.html  
AP1.11 Mouse total RNA master Panel (Clontech 636644) 
http://www.clontech.com/GB/Products/cDNA_Synthesis_and_Library_Construction/
RNA/Total_RNA_Mouse/15_Tissues?sitex=10030:22372:US  
AP1.12 Fantom CDNA clone  
http://www.dnaform.jp/products/fantom/pd f/FANTOM-PX-PY-PZ.pdf  
AP1.13 pcDNA3 with multiple cloning sites ,Invitrogen  
 http://products.invitrogen.com/ivgn/product/V79020  
AP1.14 SAP, Alkaline Phosphatases , Roche 
 http://www.mundocaracol.com/laboratorio/Docs/protocols/SAP_Roche.pdf  
AP1.15 pEGFP-N1 
 http://www.pkclab.org/PKC/vector/pEGFPN1.pdf  
AP1.16  DreamTaq Green DNA polymerase kit, Fermentas  
 http://www.fermentas.de/product_info.php?info=p1600  
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CV - Jennifer König 
 
Address:  65 Camden Road, Camden Town, London NW1 9EU   
Phone:   07867933453 
Email:   jennifer.koenig@gmx.at,  j.koenig@wibr.ucl.co.uk 
Date of birth:   07.07.1986 
Nationality:  Austrian  
 
RESEARCH EXPERIENCE  
 
 
Nov 2010 – July 2011     
Master Thesis, University College London      
Department of Experimental Medicine, Molecular Nociception Group  
 
Project title  Post- transcriptional regulation of SCN9A: an antisense transcript and RNA 
editing study 
Description  The aim of this project is to ascertain whether the SCN9A mRNA undergoes  
RNA editing and hence alters the encoded protein sequence of Nav1.7 
Techniques      Detection and amplification of SCN9 antisense mRNA  
Supervisor       Prof.John N. Wood, PhD, FRS; James Cox. PhD; 
 
July-August 2009 
Internship, Centre of Brain Research   
Department of Neuronal Cell Biology 
      
Project title Monitoring/ Detection of dendritically localized mRNA in hippocampal 
neurons   
Description  The aim of the project was to investigate changes in P Body/RNP localisation 
and distribution due to chemical induced changes in neuronal activity. In 
addition to the localisation, the overall distribution of P- Bodies within a 
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neuron was detected. Therefore the RNP and P- body number within 
dendrites was determined as well as their spatial distribution. 
Techniques By generating antisense probes complimentary to mRNAs (ARC, LimK) 
suspected to be crucial in dendritic development and P- Body marker. I 
performed several in situ hybridisations to compare RNA /P body distribution 
under various neuronal conditions (basal state, silenced and Glutamate) 
Real time imagining to determine mRNA / P body dynamics in hippocampal 
neurons. 
Supervisor   Prof Michael Kiebler, PhD; Georgia Vendra, PhD 
 
April– May 2009 
Internship, Center of Brain Research      
Department of Neuroimmunology 
 
Project title The role of CKLF1 in the EAE Mouse model of Multiple Sclerosis 
Description Certain chemokine’s preferentially enhance the migration of Th2 cells into the 
CNS.Chemokine like factor – 1 is a functional ligand of the CCR4 receptor 
and expressed on the surface of macrophages, dendritic cells and on the 
surface of Th2 cells. If Th2 cells are somehow recruited by chemokine like 
factor 1 they could function as potential key players in the shutdown of EAE 
by stimulating an immune protective pathway.   
Techniques Purification and in vitro translation of CKLF1 which used to immunization of 
EAE mouse. 
Supervisor  Monika Bradl, PhD; Prof J. Lassmann, PhD 
 
Nov – Jan 2009 
Neuroscience Program - Lab Rotation training       
  
Center of Brain Research, Medical University of Vienna      
All Departments  
Description  Practical training to acquire commonly used techniques in Neuroscience  
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Techniques Elisa, Fura Imaging, immunocytochemistry, in situ hybridisation 
measurement of electrophysical properties of neurons, microscopy and 
sample preparation Receptor binding studies, Mass- spectroscope, 
SuperFusion 
2005-2008 
Lab Courses during the 1
st
 Diploma – Vienna Biocenter     
Lab courses  
 
Molecular biology and Genetics I, IIA+ IIB, III, Cell biology  
Biochemistry, Organic chemistry, Inorganic chemistry, Microbiology I, II 
 
Techniques Acquisition of basic knowledge and skills in molecular biology for example: 
PCR, Western –, Northern blot, cloning, protein purification, DNA and RNA extraction, 
Bradford, Mass-spectrometry  
 
CAREER AIM            
 
Since my undergrad I’ve been really passionate about Neuroscience and Genetics, in 
particular RNA Biology. Recently I came to realise that I would love to further knowledge in 
Bioinformatics and DNA sequencing. 
 
EDUCATION  
 
Master Thesis   University College London     2010-2011 
   Molecular Nociception Group 
 
Masters   University of Vienna      2008-2010 
   Lectures and lab courses in Molecular Neuroscience   
   Specialization: Neuroscience, Cell biology and 
   Molecular medicine 
 
   Université Aix- Marseille III    2009-2010 
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   European exchange student. Following a course in   
   cognitive and integrative Neuroscience  
 
Undergrad   University of Vienna     2005-2008 
   1st Diploma in Molecular biology  
   Key aspect: Cell biology, Molecular biology,    
   Neuroscience, ChemistryBiology, Grade:  B; 
 
High school    Bundesoberstufenrealgymnasium (BORG)   2001-2005 
   Grieskrichen, OÖ  
   A- Level with honour  
 
INTERESTS          
 
• Languages: fluent in German and English , French good but not fluent 
• Travelling and Anthropology 
• Art expositions 
• Reading 
• Salsa 
 
WORK EXPERIENCE         
Spring 2008  Sale advisor at H&M 
 
 
 
 
 
 
 
                                                 
 
 
 
